

Sonoma Valley Community Health Center Diabetes HbA1c Control

Redwood Community Health Coalition **Promising Practice**

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number H2QCS30258, Health Center Controlled Networks, for \$1,500,000. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.

PROMISING PRACTICE OVERVIEW

Sonoma Valley Community Health Center (SVCHC) is achieving high performance on diabetes HbA1c control < 9% with a 6% improvement from 2015 to 2016 according to UDS reporting. SVCHC made several workflow changes in 2015 that have led to continued improvements. SVCHC re-wrote their clinical care guidelines, documented workflows and regularly trained staff on the changes. They also focused on data validation and making sure i2i reports were accurately mapped and started sharing care team level reports with providers. SVCHC's QI Director meets with providers when data demonstrates that adherence to the guidelines/workflow is not being followed and provides one-on-one assistance to improve the clinical quality measures for the provider's panel. Diabetic patients with A1Cs over 9 are brought in monthly for provider visits where their in-house lab is used to measure A1C monthly. An endocrinologist consultant was temporarily used as a resource for provider education about the new generation of medications. They have had success using the GLP-1 receptor antagonists for some patients.

AIM

Population for focused improvement: adult patients age 18 to 75 years with a diagnosis of Type 1 or Type 2 diabetes. Goal is reduce the number of patients with HbA1c>9 from 21% to 18% (82% Diabetes A1c Controlled <9).

MEASURES

For UDS reporting to HRSA for diabetes A1c blood sugar in control, SVCHC improved from 72% in 2015 to 78% in 2016 and they have continued to improve in 2017. Sonoma Valley is close to meeting their goal of 82%.

ACTIONS TAKEN

Between 2015 and 2016 SVCHC made the following changes that contributed to their improved performance:

- 1) SVCHC rewrote their clinical care guidelines for management of diabetic patients to support their care team model. The roles and responsibilities for managing diabetic patients with HbA1cs over 9 are documented as a procedure which outlines responsibilities for care team managers, MAs and providers. Huddle sheets printed from i2i are used by care teams during huddles and include last A1c, BMI and preventive screenings. Diabetic patients are flagged in the EHR with big red letters so their chronic condition is not missed. According to the workflow, diabetic patients with A1Cs >9 are recommended to come into the health center for monthly visits with phone calls in-between visits. HbA1cs are performed using their in-house lab monthly (in-house lab launched in January 2015).
- 2) Training of the new clinical care guidelines and workflow occur during staff meetings and ongoing. Data is used to facilitate conversations about what isn't happening and why so adherence to the guideline/workflow is improved.
- 3) SVCHC upgraded their EHR system (NextGen) template for management of diabetes and started to work on re-mapping i2i and validation of reports.
- 4) SVCHC contracted with a endocrinologist who served as a resource for one year from 2016 to 2017 and trained providers on medication management for the new generation of medications. The GLP-1 receptor antagonists have been helpful in managing patients struggling to get their A1cs under control.

In House Lab – Hemoglobin A1c PROCEDURE

From anywhere within the current encounter (The medical assistant always completes the 5

point check) click on the icon for the Orders Module on the top tool bar or at the bottom of the History bar.

(The Medical Assistant will no longer be using Standing Orders/Office Diagnostic or Office Procedures when ordering or resulting the Hemoglobin A1c)

Once in the Orders Module, click on the second internal tab for the Orders Summary.

ļ	4 1	2/14/2016 02:44 P	M : "*SOAP"	Order Module	×
	Results	Orders Summary	Immunizations		
	Orders				

New... -Now click New to order the test

At the top of the "Create New Lab Order" window, select InHouseLab as the performing entity.

Create New Lab Order for Test, Brandon									
Lab	Rad Imm								
Performing Enti	ty: InHouseLab	• 🗌 ST.							
Patient T	InHouseLab sis Marin Pathology QuestDiag Sonoma Valley Hospital sbet <to be="" determined=""></to>	day's							

From the top Select Diagnosis section select the appropriate diabetes diagnosis by clicking the checkbox next to it. The diagnoses that the Medical Assistant will see are the patient's current and chronic diagnoses. (Please Note: If there is not a diabetes diagnosis or screening for diabetes diagnosis the Medical Assistant will need to ask the provider to add the appropriate diagnoses to the patient Assessment and, if a Chronic Condition, to the Patient Problem list)

- Select Diagnosis	ic Dieck All Uncheck All	
Type 2 diabetes melitus without complication, without long-term c	Essential (primary) hypertension (110)	Major depressive disorder, recurrent, mild (F33.0)
Type 2 diabetes melitus with hyperglycenia (E11.65)	Long tem (current) use of insulin (279.4)	
DM neuro manif type II (E11.40)	Other fatigue (R53.83)	Major depretarive dicorder, recurrent, mild (F33.0)
Chronic masillary sinusitis (J32.0)	Adjustment disorder with depressed mood (F43.21)	
X		<u>x</u>

In the Select Tests section the Medical Assistant will see the HGBA1C test in the favorite's panel. Click the checkbox next to it to select the test.

Select Tests	_							
Show Favorites +	ly Calegory 🔻	This Order	Search AL.	Check.All	Uncheck All	Add to Favorites	Delete from Favorites	🗌 Use NextGen Compendium
HGBA1C (HgbA1C)								

- 5) SVCHC's QI Director e-mails reports of each provider's panel on a quarterly basis and if data shows that a provider is not following the standard procedure for management of diabetes, she will schedule an appointment on the provider's clinic schedule and bring the data in for a more in-depth review and discussion in-person. The QI Director has conducted these conversations with about 50% of the providers.
- 6) SVCHC increased referrals to their certified diabetic educator (CDE) and registered dietitian who is on staff two days a week. They also have access to a podiatrist and they do retinography in-house. LVN/case managers have a caseload of about 25 patients at a time and ensure that A1c are completed every visit.

WORKFLOWS

See attachments for documented workflows

RESULTS TO DATE

SVCHC DIABETES BLOOD SUGAR IN CONTROL (HBA1C **≤ 9%**)



LESSONS LEARNED

SVCHC has learned that while monthly A1c tests are expensive, it helps to make sure patient progress on glucose control is regularly documented and engages the patient in discussions about their lab values with their provider and nurse case manager.



Document Title: Chronic Conditions Diabo	Page 1 of 8					
Document Type: Procedure Document ID Number:						
Department: Medical						
Author: Marianne Clinton, MD CMD	Implementer/Owner: Marianne Clinton, MD CMD					
Approval Date:04/16/2014	broval Date:04/16/2014 Training Date:04/16/2014					
Implementation Date: 04/16/2014	plementation Date: 04/16/2014 Revision Date:					
Effective Date: 04/16/2014 Next Review Date: 04/01/2016						

STATEMENT OF PURPOSE:

- It is the policy of Sonoma Valley Community Health Center (SVCHC) that we provide excellent care of diabetic patients by standardizing our care processes based on recommendations of the American Diabetes Association. Work flows and policies are modeled on those of Kaiser Permanente.
- To this end, SVCHC has selected improvement in diabetes management as one of the chronic conditions for focused attention within the construct of Patient Centered Medical Home (PCMH). Specifically, goal is to reduce the number of patients with HbA1C>9 from 21% to 18%.
- Population for focused improvement adult patients age 18 to 75 years with a diagnosis of Type 1 or Type 2 diabetes.

DEFINITIONS:

Diabetes Mellitus (DM) or simply Diabetes, is a group of metabolic diseases in which a person has an elevated serum glucose. Symptoms include frequent urination, increased thirst, and increased hunger. Untreated, diabetes can cause many complications. Acute complications include diabetic ketoacidosis and nonketotic hyperosmolar coma. Long-term complications include heart disease, kidney failure, damage to the eyes, and damage to the nervous system and circulation.

- Type I DM results from the body's failure to produce insulin. This form was previously referred to as "insulin-dependent diabetes mellitus" (IDDM) or "juvenile diabetes".
- Type 2 DM results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes also with an absolute insulin deficiency. This form was previously referred to as noninsulin-dependent diabetes mellitus (NODDM) or "adult-onset diabetes".
- Gestational diabetes, is the third main form and occurs when pregnant women without a previous diagnosis of diabetes develop a high blood glucose level.

Evidence Based Guidelines: Clinical Practice guidelines based on scientific evidence; or in the absences of scientific evidence, professional standards, or in the absences of professional standards, an expert opinion.

Practice Guidelines: Systematically developed descriptive tools or standardized procedures for care to support clinician and patient decisions about appropriate health care for specific clinical circumstances. Practice guidelines are typically developed though a formal process and are based on authoritative sources that include clinical literature and expert consensus.

Important Condition: A condition including an unhealthy behavior, substance abuse or mental health issue, with evidence –based clinical guidelines that affect a large number of people or consumes a disproportionate amount of health resources.

NextGen Enterprise Practice Management (EPM): NextGen EPM is the application used primarily for billing and is also used to manage appointments. Other functions of EPM include, but are not limited to, storing patient demographics, posting transactions, and processing charges.

NextGen Electronic Health Records (EHR): NextGen EHR is the application used to store and maintain a patient's electronic chart. Clinical information such as lab results, health history, and diagnosis history are located in EHR.

History of Present Illness (HPI): The HPI is a chronological description of the development of the patient's present illness including the following elements: Location, Quality, Severity, Duration, Timing, Context, Modifying factors and associated signs and symptoms. Brief and Extended HPI's are distinguished by the amount of detail needed to accurately characterize the clinical problem or problems:

_Brief – consist of 1 to 3 elements.

Extended - consists of 4 or more elements.

BACKGROUND:

Diagnostic criteria for diagnosis of diabetes – at least one of the following: ⁱ

- A1C>=6.5%
- Fasting serum glucose >= 126. Fasting is defined as no caloric intake for at least 8 hours.
- Oral glucose tolerance test (OGTT), 2-hour plasma glucose >= 200 after 75g glucose load.
- Random plasma glucose >=200 in a patient with classic symptoms of hyperglycemia.
- In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.

ASSUMPTIONS: None

PCMH (Patient Care Medical Home) Related: Yes (X); No ()

PCMH 2, Element G: The Practice Team, Factor 3: the practice has written standing orders. PCMH Element 3, and PCMH 4.

NextGen EPM/EHR Procedure is needed for this Procedure: Yes (X); No ()

PROCEDURE:

The Care Manager/Care Team Manager is responsible for

- 1. Running and reviewing NextGen report weekly for patients with type 1 and type 2 diabetes with HgA1c >9.0.
- 2. Identifying patients due for lab and other testing, and patients with failed appointments. In addition, providers may identify other patients with co-morbidities and psychosocial risk factors that warrant closer monitoring.
- 3. Contacting patients in need of services, ordering needed tests/services per protocol, tasking the patient's Primary Care Provider (PCP) with any other needed orders, scheduling follow up appointments, and follow-up on patients who failed to keep their appointments.
- 4. Activation of patient recall for Diabetes based on diagnosis, date of last visit, and date of last recorded HbgA1C . (This responsibility may eventually be re-assigned to other staff members.)
- 5. Responding to requests from the providers.

The Medical Assistant is responsible to:

- 1. Complete review of patient's Health History ensuring past medical, family and social histories are complete and updated appropriately.
- 2. Update any recent hospitalizations/ ER visits
- 3. Obtain any appropriate medical records for the providers review
- 4. Complete tobacco assessment.
- 5. Complete full set of vitals (height, weight, blood pressure, pulse, respiratory rate, temperature).
- 6. Make sure that patient has removed their shoes and socks at each visit to facilitate completion of the foot examination.
- 7. Select Diabetes HPI as the reason for visit. (Never select Diabetes Follow-up HPI.)
- 8. Determine if patient brought a record of home glucose monitoring. If not, perform random glucose.
- 9. Review chart, obtain results, and place into the Diabetes Protocol (optimally at time of pre-visit chart preparation) the following:
 - a. Consultation report of dilated fundoscopic eye examination and/or retinal photography.
 - b. Date of last dental exam, name of dental provider, and consultation report.
 - c. Date of most recent monofilament foot exam.
 - d. Dates of most recent A1C, lipid panel, metabolic panel, and microalbumin.
- 10. Complete monofilament foot exam if not completed within last 12 months.
- 11. Provide assistance in completion of Patient Self Management Tool.
- 12. Review patient's medications.
- 13. Using a standing order, perform A1C if not done in the last 3 months (or 6 months for Medicare patients).
- 14. Provide any needed immunizations, utilizing the CAIR registry. Enter all immunization data and patient information into CAIR registry.
- 15. Perform a PHQ2 depression screen annually. If PHQ2 is positive, administer the PHQ9 depression screen.

16. Provide information regarding available education classes and community resources.

The Provider is responsible to:

- 1. Complete the Diabetes HPI (Required MU and PCMH).
- 2. Assure that diagnosis is on problem list.
- 3. Review of history information (past, family, social) at each patient visit
- 4. Perform appropriate physical examination for the diabetic patient.
- 5. Perform foot inspection at every visit with monofilament exam at least yearly. Monofilament exam may be performed by MA, and documentation reviewed by the provider.
- 6. Refer for dental examination every 6 months.
- 7. Refer for eye examination annually.
- 8. Hemoglobin A1C every 3 months (in most cases). (Medicare only pays for this service twice a year starting 1/1/2014.)
- 9. Lipid screening annually and as indicated.
- 10. Micro-albumin annually and as indicated
- 11. Complete Metabolic Panel annually and as indicated.
- 12. Immunizations up to date influenza and Pneumovax immunizations.
- 13. All patients will be referred to the SVCHC Certified Diabetes Educator for diabetes education, home glucose monitoring instruction, diet and exercise counseling.
- 14. Diabetic patients to have 2 focused visits per year with the exception of patients that have not achieved optimal blood glucose range below 8 they will be brought back for additional focused visits by the PCP on a monthly basis.

Provider identified treatment goals by current A1C level:

- A1C level >9%
 - Drug naïve
 - With symptoms insulin +/- other agents
 - No symptoms combination therapy (metformin + another oral hypoglycemic medication).
 - Under treatment insulin +/- other agents
- Recommended medication regimens:ⁱⁱ
 - Monotherapy metformin. If needed to reach individualized A1C target after 3 months, proceed to two-drug combination.
 - Two drug combinations metformin plus (listed in random order):
 - Sulfonylurea (SU)
 - Thiazolidinedione (TZD)
 - DPP-4 inhibitor (DPP-4-I)
 - GP-1 receptor agonist (GLP-1-RA)
 - Insulin (usually basal i.e. NPH, glargine, detemir)
 - Three drug combinations metformin plus (listed in random order):
 - Bulfonylurea + thiazolidinedione or SPP-4-1 or GP-1 receptor agonist or
 - Thiazolidinedione = (sulfonylurea or DPP-4 inhibitor or GP-1 receptor agonist or insulin)
 - DPP-4 inhibitor = (sulfonylurea or thiazolidinedione or insulin)
 - GP-1 receptor agonist + (sulfonylurea or thiazolidinedione or insulin)
 - Insulin + (thiazolidinedione or DPP-4 inhibitor or GP-1 receptor agonist)

Treatment Goals:

- HbA1C
 - For all patients, A1C<=8
 - Target for many patients is A1C< 7 %.
 - A more stringent A1C goal of <6.5% may be reasonable for selected patients, if this can be achieved without hypoglycemia or other adverse effects of treatment
 - A less stringent goal of A1C< 9% may be appropriate for patients with a history of hypoglycemia, limited life expectancy, advanced microvascular and macrovascular complications, or extensive comorbid conditions.
 - Minimum of HbA1C testing every 6 months. This frequency is more reliably achieved by testing every 3 months during focused diabetes visits. Patients with variable control will continue to be best managed with A1C testing every 3 months. Patients who maintain excellent control can be managed with less frequent testing, but for best care and auditing purposes, frequency must never fall below twice yearly.
- Glucose
 - Fasting glucose <110
 - Postprandial glucose <140
 - Home glucose monitoring is a key component of optimal diabetes management. Frequency of testing depends on patient's current diabetic control, use of insulin (especially short-acting sliding scale), symptoms, etc.
- Blood Pressure target optimal blood pressure which balances benefit and risk, continues to be studied. Based on Up-to-date literature review of 1/22/2013ⁱⁱⁱ, and specifically the UDPDS, HOT, and ADVANCE trials, the following treatment goals are recommended:
 - All patients with diabetes mellitus have a goal blood pressure less than 140/90 mmHg.
 - Attempt to lower the systolic pressure below 130 to 135 mmHg (preferably less than 130 mmHg) if it can be achieved without producing significant side effects (weaker recommendation).
 - Goal blood pressure of less than 130/80 mmHg in patients with diabetic nephropathy and proteinuria (500 mg/day or more). Patients with moderately increased albuminuria (formerly "microalbuminuria") are treated similarly to diabetic patients without proteinuria.
- Lipid Management
 - An LDL goal of <100, with an optional goal of <70, is recommended for all patients with diabetes.
 - See separate section on lifestyle management.
 - Statin therapy
 - Statin therapy is recommended for all patients with diabetes and coronary artery disease (CAD).
 - Statin therapy is recommended for all patients with diabetes who are 40 years of age and older.
 - Statin therapy, age 39 or younger.
 - With >=1 risk factor, statin therapy is RECOMMENDED when LDL>=100. Statin therapy is OPTIONAL when LDL<100.

- Without risk factors, statin therapy is RECOMMENDED with LDL<=130. Statin therapy is OPTIONAL when LDL<130.
- Risk factors include: duration of diabetes >=10 years, HDL<40, current smoker, or family history of premature CAD (clinical CAD or sudden death in a first-degree relative aged<55[men] and <65 [women]).
- Drug Therapy for Primary and Secondary Prevention of Cardiovascular Events
 - ACE Inhibitor Therapy drug therapy with ACE inhibitors is recommended for patients with diabetes aged>=55 years with one or more cardiovascular risk factors:
 - Total cholesterol>200
 - HDL cholesterol<=35
 - Hypertension
 - Microalbuminuria
 - Current smoking
 - History of cardiovascular disease (coronary artery disease, stroke, or peripheral vascular disease).
 - Beta-Blocker Therapy
 - For patients with coronary artery disease, non-instrinsic sympathomimetic activity beta-blocker therapy is recommended, unless contraindicated.
 - Aspirin Therapy
 - For patients >=40 years old with diabetes, treatment with at least 81mg/day aspirin is recommended unless contraindicated.
- Screening for Complications
 - Retinal screening diabetic patients with background retinopathy, or more severe disease, should be monitored at least annually. Those without retinopathy should be screened every one to two years.
 - Foot screening
 - Visual foot inspection every visit.
 - Monofilament testing at least once per year.
 - Patients with an abnormal monofilament test are at a high risk for lower limb complications and are candidates for entry into a podiatry populationbased foot care program, or equivalent.
- Lifestyle Management
 - Healthy diet The American Diabetes Association (ADA) recommends decreased calorie intake, increased physical activity to promote weight reduction, and monitoring carbohydrate intake as the primary considerations in achieving glycemic control. ADA nutritional guidelines do not give specific total dietary compositional targets, except for the following recommendations, which are in large part similar to the recommendations for the general population:
 - A diet that includes carbohydrates from fruits, vegetables, whole grains, legumes, and low-fat milk is encouraged.
 - A variety of eating patterns (low fat, low carbohydrate, Mediterranean, vegetarian) are acceptable.
 - Fat quality is more important than fat quantity. Saturated fat and trans fat contribute to coronary heart disease, while monounsaturated fats are relatively protective. Saturated fats (e.g. in meats, cheese, ice cream) can be replaced with monounsaturated and polyunsaturated fatty acids

(e.g. in fish, olive oil, nuts). Trans-fatty acid consumption should be kept as low as possible.

- A reduced sodium intake of 2300mg per day or less is prudent. For individuals with hypertension, further reduction in sodium may be necessary.
- Activity moderate exercise (e.g. walking), at least 30 minutes daily is encouraged.
- Tobacco Cessation
- Psychosocial Risk Factors

Patient Education:

- Encourage patient to make/keep appointment with diabetic educator/registered dietician and to attend available diabetes and nutrition classes. Family members are encouraged to attend as well.
- Stress the importance of healthy diet, exercise, home blood glucose monitoring, hypoglycemia signs and symptoms, and foot care.
- When insulin therapy is initiated, refer to the diabetic educator or RN for education.
- Establish and review 3 patient self-management goals.

Physician Consultation/Referral – Mid-Level Provider:

- Patients who have difficulty controlling blood glucose as well as patients who have significant co-morbidities, refer to physician provider at the health center.
- Patients with suspected diabetic ketoacidosis or hyperosmolar, nonketotic syndrome (blood glucose 500mg/dL, ketones negative), refer to the Emergency Department.
- Most patients withType 1, insulin-dependent diabetes should be referred to an endocrinologist, if feasible. Otherwise refer to a health center physician provider.

Physician Consultation/Referral – External:

- Referral to an endocrinologist when diabetic control is difficult to achieve.
- Referral to an endocrinologist for most patients with Type I diabetes.

Monitoring:

Quarterly chart audits will be performed to assure that providers are following best practices. It is acknowledged that diabetes care is nuanced, with goals individualized as noted above. At a minimum, the following measures will be monitored:

A1C \geq 9% Blood pressure < 140/90. LDL cholesterol performed annually. Referral for funduscopic eye exam at least every 2 years. Tobacco cessation counseling.

Optimally, monitoring will be performed via the electronic health record quality reports. In absence of this capability, a sampling of charts of patients with diabetes will be reviewed for each primary care provider.

References:

- Executive Summary: Standards of Medical Care in Diabetes 2014; volume 37, Supplement S5-S13. Accessed from the American Diabetes Association website, <u>www.diabetes.org</u>, 1/16/14.
- 2. Overview of Medical Medical Care in Adults with Diabetes, updated 12/19/13; UpTo Date website, <u>www.uptodate.com</u>, accessed 1/23/14.
- 3. Clinical Practice Guidelines Diabetes, Kaiser Permanente Medical Group, 2010.

POLICY THIS PROCEDURE SUPPORTS:

1. Implementation of Evidence-Based Guidelines Policy

ⁱExecutive Summary: Standards of Medical Care in Diabetes – 2014; Diabetes Care; January 2014; volume 37, no.Supplement 1 S5-S13. Accessed from American Diabetes Association website, <u>www.diabetes.org</u>, 1/16/14. ⁱⁱ Inzucchi SE, Bergenstal RM, Buse JB, et al; Management of hyperglycemia in type 2 diabes: a patient-centered approach. Position statement of the American Diabes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55(6): 1577-1596.

ⁱⁱⁱ Up to Date website, <u>www.uptodate.com</u>, Overview of Medical Care in patients with Diabetes, updated 12/18/13; accessed 1/23/14.



Document Title: Chronic Condition Diabetes	Page 1 of 8						
Document Type: Procedure	Document ID Number:						
Department: Medical Department							
Author: Marianne Clinton, MD, CMO	r: Marianne Clinton, MD, CMO CMO						
Approval Date:04/16/2014	Training Date:04/16/2014						
Implementation Date: 04/16/2014	Revision Date:						
Effective Date: 04/16/2014	Next Review Date: 04/01/2016						

STATEMENT OF PURPOSE:

It is the policy of Sonoma Valley Community Health Center that we provide excellent care of diabetic patients by standardizing our care processes based on recommendations of the American Diabetes Association. Work flows and policies are modeled on those of Kaiser Permanente.

DEFINITIONS:

Evidence Based Guidelines: Clinical Practice guidelines based on scientific evidence; or in the absences of scientific evidence, professional standards, or in the absences of professional standards, an expert opinion.

Practice Guidelines: Systematically developed descriptive tools or standardized procedures for care to support clinician and patient decisions about appropriate health care for specific clinical circumstances. Practice guidelines are typically developed though a formal process and are based on authoritative sources that include clinical literature and expert consensus.

Important Condition: A condition including an unhealthy behavior, substance abuse or mental health issue, with evidence –based clinical guidelines that affect a large number of people or consumes a disproportionate amount of health resources.

NextGen Enterprise Practice Management (EPM): NextGen EPM is the application used primarily for billing and is also used to manage appointments. Other functions of EPM include, but are not limited to, storing patient demographics, posting transactions, and processing charges.

NextGen Electronic Health Records (EHR): NextGen EHR is the application used to store and maintain a patient's electronic chart. Clinical information such as lab results, health history, and diagnosis history are located in EHR.

History of Present Illness (HPI): The HPI is a chronological description of the development of the patient's present illness including the following elements: Location, Quality, Severity, Duration, Timing, Context, Modifying factors and Associated signs and symptoms. Brief and Extended HPI's are distinguished by the amount of detail needed to accurately characterize the clinical problem or problems:

Brief – consist of 1 to 3 elements.

Extended - consists of 4 or more element

BACKGROUND:

Diagnostic criteria for diagnosis of diabetes – at least one of the following: ⁱ

- A1C>=6.5%
- Fasting serum glucose >= 126. Fasting is defined as no caloric intake for at least 8 hours.
- Oral glucose tolerance test (OGTT), 2-hour plasma glucose >= 200 after 75g glucose load.
- Random plasma glucose >=200 in a patient with classic symptoms of hyperglycemia.
- In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing.

ASSUMPTIONS: None

PCMH (Patient Care Medical Home) Related: Yes (X); No ()

PCMH 2, Element G: The Practice Team, Factor 3: the practice has written standing orders. PCMH Element 3, and PCMH 4.

NextGen EPM/EHR Procedure is needed for this Procedure: Yes (X); No ()

PROCEDURE:

The Care Manager/Care Team Manager is responsible for

- 1. Running and reviewing NextGen report weekly for patients with type 1 and type 2 diabetes.
- 2. Identifying non compliant patients, patients with poorly controlled diabetes and/or comorbidities, patients due for lab and other testing, and patients with psychosocial risk factors.
- 3. Initiating action plan for patients determined to be high risk and/or in need of more intensive care.
- 4. Contacting patients in need of services, ordering needed tests/services per protocol, tasking the patient's Primary Care Provider (PCP) with any other needed orders, and scheduling follow up appointments.
- 5. Activation of patient recall for Diabetes using diagnosis and HbgA1C last recorded value.
- 6. Responding to requests from the providers.

The Medical Assistant is responsible to:

- 1. Complete review of patient's Health History ensuring past medical, family and social histories are complete and updated appropriately.
- 2. Update any recent hospitalizations/ ER visits
- 3. Obtain any appropriate medical records for the providers review
- 4. Complete tobacco assessment and, if a tobacco user make sure provider is made aware
- 5. Complete full set of vitals.
- 6. Make sure that patient has removed their shoes and socks at each visit to facilitate completion of the foot examination and inspection.
- 7. Select Diabetes HPI as the reason for visit. (Never select Diabetes Follow-up HPI)
- 8. Determine if patient brought a record of home glucose monitoring. If not, perform random glucose.
- 9. Perform urine dip if random blood sugar > 300.
- 10. Review chart and obtain results/ consultation report of dilated fundoscopic_eye examination/ retinal photography if not already present.
- 11. Review chart/ask patient date of last dental exam.
- 12. Review chart for monofilament foot exam completion.
- 13. Complete monofilament foot exam if not completed within last 12 months.
- 14. Provide assistance in completion of Patient Self Management Tool.
- 15. Review patient's medications.
- 16. Review chart for dates of most recent A1C, lipid panel, metabolic panel, and microalbumin.
- 17. Using a standing order perform A1C if not done in the last 3 months.
- 18. Provide any needed immunizations. Use and enter all immunization data and patient information into CAIRS registry.
- 19. Perform a PHQ2 depression screen annually. If PHQ2 is positive, administer the PHQ9 depression screen.
- 20. Provide information regarding available education classes and community resources.

The Provider is responsible to:

- 1. Complete the Diabetes HPI (Required MU and PCMH).
- 2. Assure that diagnosis is on problem list.
- 3. Review of history information (past, family, social) at each patient visit
- 4. Perform appropriate physical examination for the diabetic patient.
- 5. Perform foot inspection at every visit with monofilament exam at least yearly.
- 6. Refer for dental examination every 6 months.
- 7. Refer for eye examination annually.
- 8. Hemoglobin A1C every 3 months (in most cases). (Medicare only pays for this service twice a year starting 1/1/2014.)
- 9. Lipid screening at initial visit, then annually and as indicated.
- 10. Micro-albumin at initial visit, then annually and as indicated
- 11. Complete Metabolic Panel at initial visit, then annually and as indicated.
- 12. Immunizations up to date influenza and Pneumovax immunizations.
- 13. All patients will be referred to the SVCHC Certified Diabetes Educator for diabetes education, home glucose monitoring instruction, diet and exercise counseling.

Provider identified treatment goals by current A1C level:

- A1C level 6.5% to 7.5%:
 - Refer to Diabetes Educator
 - o Provider information on healthy diet and exercise.
 - o Initiate Monotherapy or Combination Medication Therapy.
 - o Continue current therapy if all treatment goals are met
 - Monitor/adjust therapy as needed to meet treatment goals
- A1C level 7.6% to 9.0%:
 - o Initiate Combination Therapy (if not already started)
 - o Monitor/adjust Rx to meet treatment goals.
 - Maximize Combination Therapy.
 - o Maximize Insulin Therapy
 - If elevated fasting blood sugar (FBS), add Basal
 - If elevated post-prandial glucose (PPG), add Bolus
 - If elevated FBS and PPG, add Basal-Bolus therapy or Pre-mixed insulin analogs
 - Monitor/adjust to meet treatment goals.
- A1C level >9.1%:
 - Drug naïve
 - With symptoms insulin +/- other agents
 - No symptoms combination therapy (metformin + another oral hypoglycemic medication).
 - Under treatment insulin +/- other agents
- Recommended medication regimens:ⁱⁱ
 - Monotherapy metformin. If needed to reach individualized A1C target after 3 months, proceed to two-drug combination.
 - Two drug combinations metformin plus (listed in random order):
 - Sulfonylurea (SU)
 - Thiazolidinedione (TZD)
 - DPP-4 inhibitor (DPP-4-I)
 - GP-1 receptor agonist (GLP-1-RA)
 - Insulin (usually basal i.e. NPH, glargine, detemir)
 - Three-drug combinations metformin plus (listed in random order):
 - SU + (TZD or SPP-4-I or GLP-1-RA or insulin)
 - TZD + (SU or DPP-4-I or GLP-1-RA or insulin)
 - DPP-4-I + (SU or TZD or insulin)
 - GLP-1-RA+ (SU or TZD or insulin)
 - Insulin + (TZD or DPP-4-I or GLP-1-RA)

Treatment Goals:

- HbA1C
 - For all patients, A1C<=8
 - Target for many patients is A1C< 7 %.
 - A more stringent A1C goal of <6.5% may be reasonable for selected patients, if this can be achieved without hypoglycemia or other adverse effects of treatment
 - A less stringent goal of A1C< 9% may be appropriate for patients with a history of hypoglycemia, limited life expectancy, advanced microvascular and macrovascular complications, or extensive comorbid conditions.

- Minimum of HbA1C testing every 6 months. This frequency is more reliably achieved by testing every 3 months during focused diabetes visits. Patients with variable control will continue to be best managed with A1C testing every 3 months. Patients who maintain excellent control can be managed with less frequent testing, but for best care and auditing purposes, frequency must never fall below twice yearly.
- Glucose
 - Fasting glucose <110
 - Postprandial glucose <140
 - Home glucose monitoring is a key component of optimal diabetes management.
 Frequency of testing depends on patient's current diabetic control, use of insulin (especially short-acting sliding scale), symptoms, etc.
- Blood Pressure target optimal blood pressure which balances benefit and risk, continues to be studied. Based on Up-to-date literature review of 1/22/2013ⁱⁱⁱ, and specifically the UDPDS, HOT, and ADVANCE trials, the following treatment goals are recommended:
 - All patients with diabetes mellitus have a goal blood pressure less than 140/90 mmHg.
 - Attempt to lower the systolic pressure below 130 to 135 mmHg (preferably less than 130 mmHg) if it can be achieved without producing significant side effects (weaker recommendation).
 - Goal blood pressure of less than 130/80 mmHg in patients with diabetic nephropathy and proteinuria (500 mg/day or more). Patients with moderately increased albuminuria (formerly "microalbuminuria") are treated similarly to diabetic patients without proteinuria.
- Lipid Management
 - An LDL goal of <100, with an optional goal of <70, is recommended for all patients with diabetes.
 - See separate section on lifestyle management.
 - Statin therapy
 - Statin therapy is recommended for all patients with diabetes and coronary artery disease (CAD).
 - Statin therapy is recommended for all patients with diabetes who are 40 years of age and older.
 - Statin therapy, age 39 or younger.
 - With >=1 risk factor, statin therapy is RECOMMENDED when LDL>=100. Statin therapy is OPTIONAL when LDL<100.
 - Without risk factors, statin therapy is RECOMMENDED with LDL<=130. Statin therapy is OPTIONAL when LDL<130.
 - Risk factors include: duration of diabetes >=10 years, HDL<40, current smoker, or family history of premature CAD (clinical CAD or sudden death in a first-degree relative aged<55[men] and <65 [women]).
- Drug Therapy for Primary and Secondary Prevention of Cardiovascular Events
 - ACE Inhibitor Therapy drug therapy with ACE inhibitors is recommended for patients with diabetes aged>=55 years with one or more cardiovascular risk factors:
 - Total cholesterol>200
 - HDL cholesterol<=35
 - Hypertension

- Microalbuminuria
- Current smoking
- History of cardiovascular disease (coronary artery disease, stroke, or peripheral vascular disease).
- Beta-Blocker Therapy
 - For patients with coronary artery disease, non-instrinsic sympathomimetic activity beta-blocker therapy is recommended, unless contraindicated.
- Aspirin Therapy
 - For patients >=40 years old with diabetes, treatment with at least 81mg/day aspirin is recommended unless contraindicated.
- Screening for Complications
 - Retinal screening diabetic patients with background retinopathy, or more severe disease, should be monitored at least annually. Those without retinopathy should be screened every one to two years.
 - Foot screening
 - Visual foot inspection every visit.
 - Monofilament testing at least once per year.
 - Patients with an abnormal monofilament test are at a high risk for lower limb complications and are candidates for entry into a podiatry populationbased foot care program, or equivalent.
- Lifestyle Management
 - Healthy diet The American Diabetes Association (ADA) recommends decreased calorie intake, increased physical activity to promote weight reduction, and monitoring carbohydrate intake as the primary considerations in achieving glycemic control. ADA nutritional guidelines do not give specific total dietary compositional targets, except for the following recommendations, which are in large part similar to the recommendations for the general population:
 - A diet that includes carbohydrates from fruits, vegetables, whole grains, legumes, and low-fat milk is encouraged.
 - A variety of eating patterns (low fat, low carbohydrate, Mediterranean, vegetarian) are acceptable.
 - Fat quality is more important than fat quantity. Saturated fat and trans fat contribute to coronary heart disease, while monounsaturated fats are relatively protective. Saturated fats (e.g. in meats, cheese, ice cream) can be replaced with monounsaturated and polyunsaturated fatty acids (e.g. in fish, olive oil, nuts). Trans-fatty acid consumption should be kept as low as possible.
 - A reduced sodium intake of 2300mg per day or less is prudent. For individuals with hypertension, further reduction in sodium may be necessary.
 - Activity moderate exercise (e.g. walking), at least 30 minutes daily is encouraged.
 - Tobacco Cessation

Patient Education:

• Encourage patient to make/keep appointment with diabetic educator/registered dietician and to attend available diabetes and nutrition classes. Family members are encouraged to attend as well.

- Stress the importance of healthy diet, exercise, home blood glucose monitoring, hypoglycemia signs and symptoms, and foot care.
- When insulin therapy is initiated, refer to the diabetic educator or RN for education.
 Establish and review 3 patient self-management goals.

Physician Consultation/Referral – Internal (Mid-Level Provider):

- Patients who have difficulty controlling blood glucose as well as patients who have significant co-morbidities.
- Patients with suspected diabetic ketoacidosis or hyperosmolar, nonketotic syndrome (blood glucose 500mg/dL, ketones negative)
- All Type 1 Insulin-Dependent Diabetics.
- •

Physician Consultation/Referral – External:

- Referral to an endocrinologist when diabetic control is difficult to achieve.
- Referral to an endocrinologist for most patients with Type I diabetes.

Monitoring:

Quarterly chart audits will be performed to assure that providers are following best practices. It is acknowledged that diabetes care is nuanced, with goals individualized as noted above. At a minimum, the following measures will be monitored:

A1C < 9% Blood pressure < 140/90. LDL cholesterol performed annually. Referral for fundoscopic eye exam at least every 2 years. Tobacco cessation counseling.

Optimally, monitoring will be performed via the electronic health record quality reports. In absence of this capability, a sampling of charts of patients with diabetes will be reviewed for each primary care provider.

References:

- 1. Executive Summary: Standards of Medical Care in Diabetes 2014; volume 37, Supplement S5-S13. Accessed from the American Diabetes Association website, <u>www.diabetes.org</u>, 1/16/14.
- 2. Overview of Medical Medical Care in Adults with Diabetes, updated 12/19/13; UpTo Date website, <u>www.uptodate.com</u>, accessed 1/23/14.

POLICY THIS PROCEDURE SUPPORTS:

1. Implementation of Evidence-Based Guidelines Policy

ⁱExecutive Summary: Standards of Medical Care in Diabetes – 2014; Diabetes Care; January 2014; volume 37, no.Supplement 1 S5-S13. Accessed from American Diabetes Association website, <u>www.diabetes.org</u>, 1/16/14.

ⁱⁱ Inzucchi SE, Bergenstal RM, Buse JB, et al; Management of hyperglycemia in type 2 diabes: a patient-centered approach. Position statement of the American Diabes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55(6): 1577-1596.

ⁱⁱⁱ Up to Date website, <u>www.uptodate.com</u>, Overview of Medical Care in patients with Diabetes, updated 12/18/13; accessed 1/23/14.



Document Title: In-House Lab - Hemoglobir	A1c	Page 1 of 8				
Document Type: Procedure	Document ID Number:					
Department: Medical Department						
Author: Julie Laird, IT Manager Implementer/Owner: Phiroze Kazi, MD, CM						
Approval Date: 12/1/2013 Training Date: 12/20/2016						
Implementation Date: 12/1/2013	Revision Date: 12/15/2016					
Effective Date: 12/01/2013	Next Review Date: 12/1/2017					

STATEMENT OF PURPOSE:

This procedure provides guidelines for the In-House Hemoglobin A1c testing resulting and submission of charges. This procedure does not change the Back Office procedure for obtaining and completing the individual patient test.

DEFINITIONS:

NextGen Enterprise Practice Management (EPM): NextGen EPM is the application used primarily for billing and is also used to manage appointments. Other functions of EPM include, but are not limited to, storing patient demographics, posting transactions, and processing charges.

NextGen Electronic Health Records (EHR): NextGen EHR is the application used to store and maintain a patient's electronic chart. Clinical information such as lab results, health history, and diagnosis history are located in EHR.

Provider Approval Queue (PAQ): The PAQ contains all items that need a provider's approval/signature. These items include but are not limited to the following:

Lab Orders

Scanned images from NextGen ICS: consultation reports, outside provider records, hospital record, diagnostic report, specialty OB lab, other lab results, other specialty lab, Health Risk Assessment, CMR/suspected child abuse report

Documents generated within NextGen EHR: Master IM, PHQ9, specialty-specific chart notes (OB Master, BH Master)

Master IM: Patient progress note generated within NextGen EHR which includes information from the selected encounter. The Master IM includes vitals, patient history, physical exam findings, and orders.

EHR Tasks /Tasking: Tasks are a user's to-do items. The EHR Workflow window (also referred to as Inbox) lists tasks assigned to the current user. Tasks can be sent to another user, a group

of users, or one's own inbox. Delegates will also have the option to view tasks assigned to the provider they are a delegate for.

NextGen Image Control System (ICS): An application that is used to import, file, and view scanned images into the NextGen system. ICS images can also be opened in NextGen Electronic Health Record (EHR) and NextGen Electronic Practice Management (EPM).

Scanning: Is defined as a process in which a devised is used that optically scans images such as reports, results and other pertinent health documents and converts it to a <u>digital image</u> that is placed into specific categories for identification into the Patient Electronic Health Record in NextGen.

Order Management: Order Management is a template in NextGen EHR that shows all orders that have been placed for the patient. This template is not encounter-based and will show orders from any encounter in the patient's chart.

Provider Test Action: Provider Test Action is a template that is used by providers to document actions that need to be taken outside of face-to-face encounters. Providers may use this template to place orders and also to send tasks to other staff. A Provider Test Action document can also be generated from this template.

High Risk Patients: See Definition of High Risk Patient procedure.

Electronic Summary-of-Care Record: this consist of the last two patient progress notes, medications list, current problem list, last laboratory results (not more than 3 months old) and Diagnostic testing (not more than 3 months) as appropriate for the Specialty Care provider selected. (See Specialty Care Referral Requirements Grid)

BACKGROUND:

As of January 1, 2017, the in-house HgbA1c workflow will change to accommodate revisions NextGen made to the software. This procedure modifies a previous workflow and ensures proper documentation and reporting of testing completed at the Health Center's In-House Laboratory.

The Medical Assistant will no longer be using Standing Orders/Office Diagnostic or Office Procedures when ordering or resulting the in-house HgbA1c test.

ASSUMPTIONS:

PCMH (Patient Care Medical Home) Related: Yes (): No (X)

NextGen EPM/EHR Procedure is needed for this Procedure: Yes (X); No ()

PROCEDURES:

From anywhere within the current encounter (The medical assistant always completes the 5

point check) click on the icon for the **Orders Module** on the top tool bar or at the bottom of the History bar.

(The Medical Assistant will no longer be using Standing Orders/Office Diagnostic or Office Procedures when ordering or resulting the Hemoglobin A1c)

Once in the Orders Module, click on the second internal tab for the Orders Summary.

√ _1	2/14/2016 02:44 P	M : "*SOAP"	Order Module	×
Results	Orders Summary	Immunizations		
Orders				

Now click New to order the test.

🗅 New...

At the top of the "Create New Lab Order" window, select InHouseLab as the performing entity.

📄 Create New Lab Order for Test, Brandon								
Lab	Rad I	mm						
Performing Ent	ty: InHouseLab	▼ □ ST.						
Patient T	InHouseLab sis Marin Pathology his (Sonoma Valley Hosp	oital iday's						
🔲 🗖 Type 2 di	abet <to be="" determined:<="" th=""><th>>without</th></to>	>without						

From the top Select Diagnosis section select the appropriate **diabetes diagnosis** by clicking the **checkbox** next to it. The diagnoses that the Medical Assistant will see are the patient's current and chronic diagnoses. (**Please Note:** If there is **not a diabetes diagnosis or screening for diabetes diagnosis** the Medical Assistant will need to ask the provider to add the appropriate diagnoses to the patient Assessment and, if a <u>Chronic Condition, to the Patient</u> <u>Problem list</u>)

- Select Di	agnosis							
Patient	This Order	Search All	Check Today's	Check Chronic	Check All	Uncheck All		
🔽 Type	2 diabetes mel	itus without co	mplication, without	long-term c	Essential (pri	nary) hypertens	ion (I10)	Major depressive disorder, recurrent, mild (F33.0)
			lycemia (E11.65)		Long term (c	urrent) use of in:	sulin (Z79.4)	
DM n	suro manif type l	l (E11.40)			Other fatigue	(R53.83)		
	ic maxillary sinu				Adjustment of	isorder with dep	pressed mood (F43.21)	
4								

In the Select Tests section the Medical Assistant will see the **HGBA1C** test in the favorite's panel. Click the **checkbox** next to it to select the test.

Select Tests								
Show Favorites 🛛 👻	By Category 🔻	This Order	Search All	Check All	Uncheck All	Add to Favorites	Delete from Favorites	🗌 Use NextGen Compendium
F HGBA1C (HgbA1C)								

Click the **Save** button at the lower right of the window to **Save** the order.

Save & Task 🛛 👻	Save & Fax	Save & Print	Save & Send	Save

If the provider of record is ordering the test, they will need to task the Medical Assistant or Nurse to complete this test, please click **Save & Task** in order to task them.



To Result the order, **click on the order in** the grid on the **Orders Summary** tab so that it is selected and highlighted in dark blue.

Ŕ	Results Orders Summary Immunizations										
C	Orders										
1	7 All Labs Radiology Imm. Scheduled Expired										
[🗅 New 🝷 😰 Refresh 👶 Sign-off 🥒 Update 🚫 Cancel 🗙 Delete 🚔 Print 👻 🍻 Fax 🌩 Send										
1	Orders below are filtered.										
		Order#	Performing Entity	Encounter Date	NextGen Status	Result Status	Provider Name	Description			
	<u>v</u>	PR0117123	InHouseLab	12/14/2016 02:44 PM	Ordered	Pending	Vo, Yen-Trang Xuan	HGBA1C			

Now click on the **down arrow** next to the work **Results** at the bottom of the screen to expand that section.

ders									
	be Radiology	Imm. Scheduled Exp	irod						Manage Filte
			🔇 Cancel 🗙 Delete	🗃 Print 🔹 🌢	🖗 Fax 🜩 Ser	nd			managernice
	ow are filtered.								
	Order#	Performing Entity	Encounter Date	NextGen Status	Result Status	Provider Name	Description		Sign-off By
	PR0154363	InHouseLab	12/15/2016 05:28 PM	Ordered	Pending	Ahem MD, Carol	Hemoglobin A1c		
	PR0152104	QuestDiag	11/18/2016 08:29 AM	Ordered	Sent	VoDO, Yen-Trang Xuan	BMP		
	PR0151605	Sonoma Valley Hospital	11/16/2016 08:45 AM	Ordered	Pending	.Hospital, Testing			
	PR0127898	QuestDiag	03/09/2016 10:38 AM	Signed-Off	Final	Moore FNP, Melinda	Hepatitis C Viral RNA, Qualitative, TMA	h	loore, Melinda
	PR0127897	QuestDiag	03/09/2016 10:38 AM	Signed-Off	Final	Moore FNP, Melinda	Hepatitis C Virus RNA Quant By PCR	N	loore, Melinda
	PR0127852	Sonoma Valley Hospital	03/09/2016 10:38 AM	Signed-Off	Final	Moore FNP, Melinda	Hep C Ab	M	loore, Melinda
	PR0127850	QuestDiag	03/09/2016 10:38 AM	Signed-Off	Final	Moore FNP, Melinda	Hep C Ab	h	toore, Melinda
	PR0127849	QuestDiag	03/09/2016 10:38 AM	Signed-Off	Final	Moore FNP, Melinda	Hep C Viral RNA	h	loore, Melinda
	PR0127848	QuestDiag	03/09/2016 10:38 AM	Ordered	Pending	Moore FNP, Melinda	Hep C Ab		

With the Results panel expanded click on the **New Results Entry** tab at the bottom of the panel.

ers below are filtered.					L	1				
Order#	Performing Entity	Encounter Dat	e	NextGen Status	Result Statu:	e Pro	vider Name			Descripti
PR0117123	InHouseLab	12/14/2016 02:44 Pt	vl Or	dered	Pending	Vo, Yen-Tra	ng Xuan	HGBA1C		
PR0117121	Sonoma Valley Hospital	12/14/2016 02:44 Pt	vl Or	dered	Pending	Vo, Yen-Tra	ng Xuan	Amylase		
Results (new results ent										
	ish 🥒 Clear 🗙 Delete 📱	Save Result Status	Final		•					
Panel : HGBA1C (HgbA Panel Comment	(1C) (1 item)									Coll. Date/Tim
ranei Comment										LOII. Date/ I IM
Comp. Key	Component		Result	Unit	Flag I	Range	Coding System	Obs. Date/Time	Result Co	nment
HgbA1C	Hemoglobin A1C					-	IH			
natted Results Grid R	esults Documents, Images a	nd Uris New Besults F	- ntru Nev	v Document	and Images Er	itrv				
Sign-off Comments	,	- How Hodding E								

Finally click in the Result field and **type the result**, <u>make sure to **only use numbers and a**</u> <u>decimal place when necessary. Do Not use:</u> Letters (HBA1C) or Symbols(%,<,>)

entry)									
lefresh 🥒 Clear 🗙 Delete 🔒 Sav	ve Result Status Final		•						
A1c (HgbA1C) (1 item)									
								Coll. Date/Time	
								<i>II</i> :	
Component	Result	Unit	Flag	Range	Coding System	Obs. Date/Time	Result C	iomment	
HgbA1c	5.8				IH				
	A1c (HgbA1C) (1 item)	lefresh 🖉 Clear 🗙 Delete 📮 Save Result Status Final A1c (HgbA1C) (1 item) Component Result	lefresh 🖉 Clear 🗙 Delete 📮 Save Result Status Final A1c (HgbA1C) (1 item) Component Result Unit	lefresh ∥ Clear 🗙 Delete 🕁 Save Result Status Final - A1c (HgbA1C) (1 item) Component Result Unit Flag	lefresh 🖉 Clear 🗙 Delete 📮 Save Result Status Final - A1c (HgbA1C) (1 item) Component Result Unit Flag Range	lefresh 🖉 Clear 🗙 Delete 🔛 Save Result Status Final - A1c (HgbA1C) (1 item) Component Result Unit Flag Range Coding System	lefresh 🖉 Clear 🗙 Delete 📮 Save Result Status Final A1c (HgbA1C) (1 item) Component Result Unit Flag Range Coding System Obs. Date/Time	lefresh 🖉 Clear 🗙 Delete 🕁 Save Result Status Final A1c (HgbA1C) (1 item) Component Result Unit Flag Range Coding System Obs. Date/Time Result C	lefresh 🖉 Clear 🗙 Delete 🖬 Save Result Status Final - A1c (HgbA1C) (1 item) Coll. Date/Time //: Component Result Unit Flag Range Coding System Obs. Date/Time Result Comment

Then select **Coll Date** /**Time** to ensure the result will show on the Lab Module in the <u>result grid</u>. A calendar will appear with today's date highlighted. Please select the correct date of the test.

Image: New index in	anel : Hemoglobi	n A1c (HgbA1C) (1 item)									
Sey Component Result Unit Flag Range Coding System Obs. Date/Time Result Omment Sun Mon Tue Wed To Sun Mon Tue Sun Mon Tue<	anel Comment									Coll. Date/Time	
HgbA1C HgbA1c 58 I I III Sun Mon Tue Wed Thu Sun Mon T										//:	
HgbA1C HgbA1c 5.8 IH Sun Mon Tue Wed Thu 25 26 27 28 29 1 2 3 4 5 8 9 10 11 12 15 16 17 18 22 3 4 5	omp. Key	Component	Result	Unit	Flag	Range	Coding System	Obs. Date/Time	Result 0	omment	1 January 2017
25 26 27 28 29 1 2 3 4 5 8 9 10 11 12 15 16 17 18 19 12 23 24 25 26	HgbA1C	HgbA1c	5.8				IH				
22 23 24 25 26											
22 23 24 25 26											1 2 3 4 5 6
22 23 24 25 26											8 9 10 11 12 13
											29 30 31 1 2 3

Now click **Save** in the row just a little above where the Medical Assistant entered the result. This **submits** the **CPT code for billing** as well **saves** the result into the Orders Module of the **chart** and for display into the **master document**.



Along with being able to view the results in this results panel in the future as a **Formatted Result**,

Results (reported results - formatted)							
Show Normal (N) Results Flag Show Compressed Res	sults 🗌 MU Compatible 🚯 Refresh 🎒 Print 🔻 🏟 Fa:	💽 Full	Screen 🛍 Co	py 🚉 Selec	lect All 💿 Setup		
Sonoma Valley Comm Health Center Test, Brandon 19270 Sonoma Highway 12 19548 Orange Ave Sonoma, CA, 954765414 Sonoma, CA, 95476 Person #: 22447 Person #: 22447 DOB: 03/01/1975 Sonoma, CA, 95176							
Ordering: Vo, Yen-Trang Xuan Tests Ordered : HGBA1C (HgbA1C)	Performing #: InHouseLab				Location: SVCHC		
HGBA1C (Collection Date: 12/14/2016 17:22 *, Statu				_			
Component	Result	Units	Flag	Range	Comment		
Hemoglobin A1C	12						

The Medical Assistant can see it on the **Results** tab in the Orders Module. The Provider or Medical Assistant has the ability to **graph** the results by clicking on the result component **row** (the row that spells out Hemoglobin A1C) and clicking the graph button.

Please Note: This will only graph the In House Hemoglobin A1Cs, although Quest, and SVH results that are in a row can be graphed separately.

Results Orders Summary	Immunizations									
🝸 All	Y All									
View results by 👻 🕡 Resources 👻 🔲 Show Only Results 🛛 😰 Refresh 🔜 Graph										
Results are viewed by lab	Results are viewed by lab short description.									
Collection Date & Time	12/14/2016 17:22 *	12/14/2016 16:18	12/14/2016 14:46	11/30/2016 10:56						
HGBA1C										
Hemoglobin A1C	12	<u>15</u>	9.6							
Result				7.8						

In addition, results of the In-House Hemoglobin A1C's will show on the Home Page in the Labs section rather than the Office Labs section.

HPI's		12/14/2016	12/14/2016	12/14/2016	11/30/2016	06/11/2016	06/11/2016
Plans		17:22	16:18	14:46	10:56	08:04	07:58
Problem List	HGBA1C						
Medications	Hemoglobin A1C	12	15	9.6			
Allergies	Result				7.8		
Labs							

Please Note: When completing huddle sheets, staff must still look at Office Labs on the Home Page to see in-house HgA1c results prior to 12/22/216.

This procedure must be completed by the medical Assistant or Nurse before the provider finalizes the encounter in order for the test results to show on the patient's Master IM under the **In-House Module Labs section.**

_	_	_	_	_	_	_	_	_
SODICIVI	-	-	-	-	-	-	-	-
LATEX								
OXYCODONE HCL		Percocet						
HYDROCODONE		Vicodin						
BITARTRATE								

Assessment/Plan

#	Detail Type	Description
1.	Other Orders	Orders not associated to today's assessments.
	Plan Orders	Hemoglobin A1c to be performed.

In-House Module Labs (resulted today)

Lab Description	Result	Comments
HgbA1c	10.5	

Medications (Added, Continued or Stopped today)

Start Date	Medication	Directions	PRN Status	PRN Reason	Instruction	Stop Date
03/11/2015	acyclovir 200 mg capsule	take 1 capsule by oral route every 4 hours 5 times per day	N			
08/25/2014		instill by otic route 3 times every day into affected	N			

Please Note: If the procedure is not completed prior to the provider finalizing the encounter the Master IM will need to be re-generated to include the results.

POLICY THIS PROCEDURE SUPPORTS:

1. SVCHC Evidence- based Guidelines.



Document Title: Documentation of Counseli	ng Details	Page 1 of 12
Document Type: Procedure	Document ID Number:	
Department: Medical		
Author: J. Vlasis	Implementer/Owner: X. Perez, C	СМО
Approval Date: n/a	Training Date: 11/1/2016 (retrain	ר)
Implementation Date: 8/5/2016	Revision Date: 11/1/2016	
Effective Date: 8/5/2016	Next Review Date: 11/1/2018	

STATEMENT OF PURPOSE: This procedure provides guidelines for documenting counseling details, providing patient education materials and ensuring that the patient is able to comprehend information (verbal and/or written) provided to them.

DEFINITIONS:

NextGen Electronic Health Records (EHR): NextGen EHR is the application used to store and maintain a patient's electronic chart. Clinical information such as lab results, health history, and diagnosis history are located in EHR.

Healthwise: Healthwise is a helper software embedded in NextGen that provides patient education material on a variety of different medical concerns. Health education materials are presented based on age and gender and can be saved to the patient's encounter.

BACKGROUND: This is a critical measure for the New Quality Measure that we will be required to meet starting 7/1/2016 to 12/1/2017. We are in the process of setting out baseline for MACRA/MIPS which will be a payment methodology for FQHC's based solely on quality indicators and health education provided to patients.

Providers must clearly identify that they have assessed the patients: <u>Learning Preference</u>, <u>Potential Barriers</u>, and Preference for <u>Materials</u>. This is especially important for patients and families that have literacy issues. This is considered a quality measure that all payers will begin assessing for baseline starting 7/1/2016.

Counseling Details must be documented providing <u>any type of Counseling to Patients</u>. This is critical for proof of management of the patient's chronic condition or any education you are providing a patient. The simple documentation (texting) of provided instructions and counseling on the diagnosis code is no longer adequate. Providers must use counseling details and document the time spent with the patients.

This is also to be used when providing patients with information from Health Wise in NextGen. Providers must document the patients understanding and using this information for all patients is important as if shows patient education another area that will be monitored for the new Quality Measures that started actually 7/1/2016.

ASSUMPTIONS: n/a

PCMH (Patient Care Medical Home) Related: Yes (): No (X)

NextGen EPM/EHR Procedure is needed for this Procedure: Yes (); No (X)

PROCEDURES:

To document counseling details:

1. From the Finalize tab in NextGen:

Specialty Vi Family Practice Vi	sit Type V Office Visit						
Intake Histori	es SOAP	Fi	nalize	Checkout			
Order Management Document Libra	ny Procedures	Tobacco Cessal	tion]				
Care Guidelines Global Days					Panel Control:	⊙ Toggle ⊙	Cycle J
ieneral							
Foday's Assessment							C
Provider Sign Off							e
Evaluation and Management Coding							
C Straight forward C Low complexity C Moderate complexity C High complexity			Counseled grea Total visit time (Total counsel ti		and documented of the counseling of the counseli		ן ו
Valuation and Management Code Visit code:	Additional Events New patient: O 99201	&M Code * Vie Established: © 99211	W Other Codes Consultation C 99241	SNOMED Visit Type C 99381		edicare Presentive Preventive counseling:	e Codes Post Op: C 99024
Calculate Code Submit		C 99212	C 99242	C 99382	C 99391	C 99401	Prenatal:
CQM Check	C 99203	C 99213	C 99243 C 99244	C 99383 C 99384	C 99392 C 99393	C 99402	Visit 4-6:
Calculated EM code: Submitted code:	C 99204 C 99205	C 99214 C 99215	C 99244 C 99245	C 99385 C 99386	C 99394 C 99395	C 99403 C 99404	Visits greater than 6:
	Behavioral H	lealth: iitial eval, no meo	d convicos)	O 99387	C 99396 C 99397		C 59426
	C 90792 (In C 90832 (Ps	iitial eval, no med sychotherapy, 30 sychotherapy, 45	d services) minutes)	C 90847 (Fami	ly/Couple therapy, y ly/Couple therapy, y ip therapy)		

- 2. Select the Blue Counseling Details Button <u>Please note you cannot add time without</u> <u>complete documentation.</u>
- 3. Select type of counseling from the drop down box.
- 4. This is default for the last review please make sure you change to detailed document each time.

Document Title:	Documentation of Counseling Details
-----------------	-------------------------------------

			Total counselin	g time (minutes):	
Counseling/Educational Detai					
	ling of three minutes or more, please u				-
ype of counseling:	Method of counselin	ng: Evaluation of counseling:	Counselor:	Date:	Tim
					-
				11	느
				11	<u> </u>
				11	_
				11	
Comments:					
				11	
				11	
ducational materials:					
	guage: Int	terpreter's name: Rela	itionship:		
Interpreter used					
counseling/Educational Facto					
Detailed document	Reviewed		Cultural/spiritual nee	ds: 🔿 No 🔿 Yes	
(eaumess concorn)	Barriers to learning:	Learning preferences:			
Accepting	None	No preferences			
Anxious	Age	Audio materials			
Angry	Cognitive limitations	Demonstrations	Marital status:		
Angry In denial	Cognitive limitations	 Demonstrations Written materials 	D		
Angry In denial Motivated	Cognitive limitations Cultural Financial	Demonstrations			
Angry In denial	Cognitive limitations	 Demonstrations Written materials Verbal explanations 	D Race:		
Angry In denial Motivated Other (specify):	Cognitive limitations Cultural Financial Language:	 Demonstrations Written materials Verbal explanations Video materials 	D Race: White		
Angry In denial Motivated Other (specify):	Cognitive limitations Cultural Financial Language:	 Demonstrations Written materials Verbal explanations Video materials 	D Race:		
Angry In denial Motivated Other (specify):	Cognitive limitations Cultural Financial Language: Interpreter needed	 Demonstrations Written materials Verbal explanations Video materials 	D Race: White		
Angry In denial Motivated Other (specify):	Cognitive limitations Cultural Financial Language: Interpreter needed Physical limitations	 Demonstrations Written materials Verbal explanations Video materials 	D Race: White		
Angry In denial Motivated Other (specify):	Cognitive limitations Cultural Financial Language: Interpreter needed Physical limitations Reading ability	 Demonstrations Written materials Verbal explanations Video materials 	D Race: White		

- 5. The information on this template defaults from the last time it; please make sure you change to detailed document each time.
- 6. Select the Type of Counseling

Counseling/Educational Details:		
For tobacco cessation counseling	Select type of counseling	essati
Type of counseling:		of cou
Type of coursening.		or cou
	advance directives	
	alcoholism counseling	
	anticipatory guidance	
	blood glucose monitoring	
	cancer prevention cancer screening	
	chemotherapy	
Comments:	childcare	
	community resources continuation of care at home	
	diagnosis	
	diagnostic test(s)	
	dialysis	
Educational materials:	diet disease management	
	feeding breastfeeding	
	fever reduction	
Languag	foot care	
Interpreter used	health care facility health maintenance	
Counseling/Educational Factors:	HIPAA information	
	illness/disease	
O Detailed document	immunizations insulin administration	
Readiness to learn:	medical equipment	refere
Accepting	medication(s)	erenc
Anxious	medication(s) administration	hateri
Angry	pain management	stratio
In denial	patient rights/responsibilities	mate
Motivated	personal hygeine	explan
	physical activity potential food/drug interaction	
Other (specify):	PPD	nateria
Loss Medications	reach out and read	pecif
	rehabilitation techniques safe sex	
	sare sex seat belt use	
	sexually transmitted diseases	
	skin care	
	Staying Healthy Assessment	
	substance abuse counseling	
	tobacco cessation (less than 3 minutes)	
	transfusion/reaction treatment(s)	
	wellness promotion	
	· · ·	
	Close	ed se

7. Identify the Method of Counseling and Evaluation of Counseling by using the drop down boxes for Method of Counseling and Evaluation of Counseling.

ounseling Details				
Counseling/Educational Details:			Total counseling time (minutes):	
(For tobacco cessation counseling	of three minutes or more, please use t		,	
Type of counseling:	Method of counseling:	Evaluation of counseling		Time:
diet	verbal explanations			2015
			accepted the material needs reinforcement	
			refused	
	,	<u></u>	returned the demonstration verbalized an understanding	
]	- <u> </u>	was not receptive	
Comments:				
			Close	
				Rectangular Si
				- Salar Si
Educational materials:				

- 8. The provider can add 5 different topics for each patient. *Please note that each topic must have its own time.*
- 9. Place the number of minutes spent.
- 10. Please use the comment line for all additional information that you as a provider would like to add.
- 11. Make sure that you select Detailed Document.
- 12. If you used an interpreter (even if it is a member of our staff or if you are speaking to the patient directly using another language), please check the Interpreter Used box and document who provided the interpretation.
- 13. Please select the appropriate boxes in each of the three categories listed:
 - a. Readiness to Learn,
 - b. Barriers to Learning; and
 - c. Learning Preference.

Document Title:	Documentation of Counseling Details
-----------------	-------------------------------------

			Total counselin	ig time (minutes): 7
ounseling/Educational D				
or topacco cessation cou pe of counseling:	Inseling of three minutes or more, Method of co	please use the Tobacco Cessation template.) unseling: Evaluation of counseling:	Counselor:	Date: Time:
diet	verbal explai			05/18/2015 7
	, .			
	I			
				11
omments: Patient accreted material	s for diet and referral to Dietician f	or additional bein	Julie Vlasis	05/18/2015
ratient accpeted material	s for the and referral to Dietician i		Julie viasis	03/10/2013
				11
ducational materials:				
	ere. If using NextGen Education ma	ake sure to save to encounter.	_	
	erer ir doling Hexcoen Eddeadon ink			
	anguage:	Interpreter's name: Ke	lationship:	
Interpreter used	anguage: Spanish	Interpreter's name: Ke	nationship: mployee	
Interpreter used	anguage: Spanish	Interpreter's name: Ke	mployee	
Interpreter used	anguage: Spanish	Interpreter's name: Ke		ds: C No C Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn:	anguage: Spanish actors:	Ellie e	mployee	ds: Ĉ No Ĉ Yes
Tinterpreter used ourseling/Educational F Detailed document eadiness to learn: Accepting	anguage: Spanish actors: C Reviewed Barriers to learning: None	Learning preferences:	mployee	ds: Ĉ No Ĉ Yes
Tinterpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious	anguage: Spanish actors: Barriers to learning: None Age	Learning preferences:	mployee	ds: Ĉ No Ĉ Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry	Anguage: Spanish actors: C Reviewed Barriers to learning: None Age C Cognitive limitations	Learning preferences:	Cultural/spiritual nee	ds: Ĉ No Ĉ Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial	Anguage: Spanish actors: C Reviewed Barriers to learning: None Age C Cognitive limitations C Cultural	Learning preferences: Audio materials Written materials	Cultural/spiritual nee	ds: C No C Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial Motivated	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial	Learning preferences: Audio materials Written materials	Cultural/spiritual nee Cultural/spiritual nee Marital status: D Race:	ds: C No C Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial Language:	Interpreter's name: Ref Ellie e Learning preferences: No preferences: Audio materials Demonstrations Written materials Verbal explanations Video materials Video materials	Cultural/spiritual nee	ds: C No C Yes
Tinterpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial Motivated	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial	Learning preferences: Audio materials Written materials	Cultural/spiritual nee Cultural/spiritual nee Marital status: D Race:	ds: C No C Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial Motivated	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial Language: Interpreter needed	Interpreter's name: Ref Ellie e Learning preferences: No preferences: Audio materials Demonstrations Written materials Verbal explanations Video materials Video materials	Cultural/spiritual nee Cultural/spiritual nee Marital status: D Race:	ds: C No C Yes
Tinterpreter used Unseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial Motivated	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial Language: Interpreter needed Physical limitations	Interpreter's name: Ref Ellie e Learning preferences: No preferences: Audio materials Demonstrations Written materials Verbal explanations Video materials Video materials	Cultural/spiritual nee Cultural/spiritual nee Marital status: D Race: White	ds: C No C Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial Motivated	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial Language: Interpreter needed Physical limitations Reading ability	Interpreter's name: Ref Ellie e Learning preferences: No preferences: Audio materials Demonstrations Written materials Verbal explanations Video materials Video materials	Cultural/spiritual nee Cultural/spiritual nee Marital status: D Race: White	ds: C No C Yes
Interpreter used ounseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial Motivated	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial Language: Interpreter needed Physical limitations	Interpreter's name: Ref Ellie e Learning preferences: No preferences: Audio materials Demonstrations Written materials Verbal explanations Video materials Video materials	Cultural/spiritual nee Cultural/spiritual nee Marital status: D Race: White	ds: C No C Yes
Tinterpreter used Unseling/Educational F Detailed document eadiness to learn: Accepting Anxious Angry In denial Motivated	Anguage: Spanish actors: Barriers to learning: None Age Cognitive limitations Cultural Financial Language: Interpreter needed Physical limitations Reading ability	Interpreter's name: Ref Ellie e Learning preferences: No preferences: Audio materials Demonstrations Written materials Verbal explanations Video materials Video materials	Cultural/spiritual nee Cultural/spiritual nee Marital status: D Race: White	ds: C No C Yes

14. Remember to Save and Close when you are finished

Patient Counseling Complete when Counseling Details turns pick and the total counsel time appears in the box (see below).

This also increased the level of visit provided automatically as the system has a built in points score that is used for all Medicare Audits.

Evaluation and Management Coding	$\overline{\mathbf{O}}$	
Medical Decision Making View MDM Guidelines View Risk Table C Straight forward C Low complexity C Moderate complexity C High complexity	Counseling Counseled greater than 50% of time and documented content Total visit time (minutes): Total counsel time (minutes): 7)
5		

Healthwise Information for Patient Education:

1. Go to file and review the drop down box. Find Patient Education.

🍖 NextGen EHR: Deborah T Kord DOB: 11	/10/1951 AGE: 64	years 8 months (Female) MRN: 00	0000010118 - Me	dications Module		_ <u>5</u> ×
File Edit View Tools Admin Utilit	ies Window Hel	p				
New	•	urse, RN	20 20 1 2	A 🙆 🐔	X 14	
Select Patient Alt + P	- 14	dise, Riv	Patient History Inb	ox PAR PM DM		at #
Modify Patient	/10/1951 (64 yea	rs) Weight: 130.50 lb (5	9.19 Kg)	Allergie	es 🌒 Problems	Bignoses Medication Contraction Contractio
Close Patient		Insurance: Meritage Medical G	rou			PCP: Vo, Yen-Trang Xuan DO
	76	Nickname:			Ret	ferring:
Save Close	(H) F	Pref. Language: English			Ren	idering: Vo, Yen-Trang Xuan DO
X Close		Patient Info 🛛 🔶 Sti	ky Note 🐟 Refer	ing Provider 🔶 H	IPAA Advanc	e Directives Screening Summary
Print	08/02/2016 10:30 4	M : "Immunizations - Adult" / Mer	dications Module	v]		6
Custom Print \ Send		in minute and the minute	siculous module	<u>^</u>		
Export Patient Documents	Preferences					64 year Old Female Weighing 130.50 lb 59.19 Kg [vitals recorded on 8/2/2016] ESI1 Eligible
Generate CCD	1	Generic Name	Original Start	Start Date	Stop Date	
Graph						
Reports	http://www.icg-50 mttp://www.icg-50 mttp://www.icg-50 mttp://www.icg/dose p	ATORVASTATIN CALCIUM	03/10/2016	03/10/2016 05/02/2016		
	600 mg (1,500 m			05/02/2016		
ChartMail	10 mg capsule	DOCUSATE SODIUM	03/22/2016	03/22/2016		
Family Unit		FERROUS SULFATE				
HIE Consent	-acetaminophen 3	. HYDROCODONE/ACETAMINOPHEN	03/21/2016	03/21/2016		
Patient Portal	ncg tablet	LEVOTHYROXINE SODIUM	08/03/2016	08/03/2016		
Patient Education		LISINOPRIL	04/28/2016	08/02/2016		
Patient Group	25 mg tablet	METOPROLOL TARTRATE	05/02/2016	05/02/2016		
Summary	RATE 50 MG TAB	METOPROLOL TARTRATE INHALER, ASSIST DEVICES	07/14/2016 12/18/2015	07/19/2016 12/18/2015		
Superbill	p g/actuation aeros		12/18/2015	12/18/2015		
System \ Practice Template	ł	RIVAROXABAN				
Work Flow Alt + F3						
User Workgroups Alt + F5	et, delayed release	ASPIRIN			03/22/2016	
Provider Approval Queue F8	g tablet	AZITHROMYCIN	01/20/2016	01/20/2016	01/24/2016	
	-	CALCIUM CARBONATE			04/28/2016	
Change Enterprise/Practice	ncg tablet ncg tablet	LEVOTHYROXINE SODIUM	07/17/2014 07/17/2014	07/17/2014	01/06/2015	-
		tions • 🎘 Stop • 🕡 Resources • 1				Interny To Decordia
Exit Alt + X	new · @ Incerded	ions • 🕝 stop • 😈 Kesources • r	Jose Kalige X De	toto La RA Eligiblik	- ER Medicadori II	Has Been Dispensed / Encounter Is Locked
Advair Diskus 100 mcg-50 mcg/						
Sig: inhale 1 puff by inhalation route 2 times	every day in the morni	ing and evening approximately 12 hours a	part Remove Sig E	dit Sig		
Quantity: 1 Units: In	anler	Refils: 3 🔲 Dispense As 🕯	dittan	Accept	Cancel	1
		Duration:				
		I				
Non-Clinical This field is for nonclinical com Notes to Any additional clinical instruction	nents to the pharmacia ns for this prescription :	t PBN should be Poblem	Reason:			
Opens a patient education document						**PROD DB*** Sonoma Valley Comm Health Center Iviasis CAPINUM SCRU08/05/2016
opens a patient education document						

2. Search for the Educational Materials that you are looking for in the Search Criteria:

a bi

Patient Education Browser	
Search Criteria	👻 🔎 Search 🦓 English Term Age: [45 - 64 Years] Female 👻
Language English	
Allergy and Immunology Cardiovascular Cardiovascular Dematology Diabetes and Endocrinology Ear Forms and Consents Gastrointestinal Genetics Heath Health and Psychology Infectious Disease Mental Health and Psychology Neurology Neurology Neurology Nose and Throat Nutrition and Exercise Dincology Oncology Pain Management Pediatrics Pre- and Postnatal Care Pre- and Post-Op Pre- and Post-Op	
NGProd (NGSQL2.NGProd)	Select Send to Patient Portal Save to Encounter Cancel
proloi tartrate 25 mg tablet	take 1 tablet by oral route 2 times every day
PROLOL TARTRATE 50 MG TAB	take 1 tablet by mouth every 12 hours
: Chamber Plus	Use daily with steroid inhaler
plin HFA 90 mcg/actuation aerosol inhaler	inhale 2 puff by inhalation route every 4 - 6 hours as needed for cough take 1 tablet by oral route every day.
:o 10 mg tablet	take 1 tablet by oral route every day

- 3. For the specific search below, there were 8 documents found for the patient based on <u>Search Criteria</u>, <u>Age</u>, and <u>Gender</u>.
- 4. Select the document you want.
- 5. Please change language if appropriate.
- 6. Save to the Encounter. It will show in the Encounter for the day and Front Desk will print if you have not.



If you talk to the patient following the information outlined within Healthwise's health education materials, you will have touched upon most of the expected key points.

New Medication Education

Please note that you are required to provide the patient with health education and/or written materials each time a new medication is prescribed. This is over and beyond the information that the pharmacist may provide.

You will document this education as outlined above. The written materials for the patient, however, are located in the medication module.

1. From the medication module and, after you have prescribed the medication, highlight the medication in question.

- 2. Go to Resources
- 3. Select External Patient Education

Active Keflex 500 mg capsule CEPHALEXIN 07/20/2016 07/20/2016 Active Tylenol 325 mg tablet ACETAMINOPHEN 06/15/2016 06/15/2016 06/15/2016 Active Augmentin 250 mg-62.5 mg/5 mL oral suspension AMOXICILIIN/POTASSIUM CLAV 03/31/2016 03/31/2016 Active Aspirin Childrens 81 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg-325 mg tablet HYDROCOONE/ACETAMINOPHEN 11/30/2015 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL III III	Active Keflex 500 mg capsule CEPHALEXIN 07/20/2016 07/20/2016 Active Tylenol 325 mg tablet ACETAMINOPHEN 06/15/2016 06/15/2016 03/31/2016 Active Augmentin 250 mg-62.5 mg/5 mL oral suspension AMOXICILLIN/POTASSIUM CLAV 03/31/2016 03/31/2016 03/31/2016 Active Aspirin Childrens 81 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN 03/31/2016 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Acetaminophenen Songraphenen Image: Prescribe New Prime Prime Resources - Dose Range Delete Rx Engibility Monograph External Patient Education Clinical Decision Support External Provider Reference Coept Cance </th <th>Statu</th> <th>us Me</th> <th>dication N</th> <th>ame</th> <th></th> <th>Generic Nam</th> <th>ne</th> <th>Original Start</th> <th>Start Date</th> <th></th>	Statu	us Me	dication N	ame		Generic Nam	ne	Original Start	Start Date	
Active Tylenol 325 mg tablet ACETAMINOPHEN 06/15/2016 06/15/2016 Active Augmentin 250 mg-62.5 mg/5 mL oral suspension AMOXICILLIN/POTASSIUM CLAV 03/31/2016 03/31/2016 Active Aspirin Childrens 81 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN 03/31/2016 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or Cocept Delete Rx Englibility	Active Tylenol 325 mg tablet ACETAMINOPHEN 06/15/2016 06/15/2016 Active Augmentin 250 mg 42.5 mg/5 mL oral suspension AMOXICILIN/POTASSIUM CLAV 03/31/2016 03/31/2016 Active Apprint Childrens 81 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg -325 mg tablet HYDROCODONE/ACETAMINOPHEN 03/31/2016 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Monograph External Patient Education Sig: take 1 capsule by oral route eve	Status: A	Active (7 items)								
Active Augmentin 250 mg-62.5 mg/5 mL oral suspension AMOXICILLIN/POTASSIUM CLAV 03/31/2016 03/31/2016 Active Aspirin Childrens 81 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN 03/31/2016 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Moreorapsule Image: Comparison of the provide response of the pro	Active Augmentin 250 mg-62.5 mg/5 mL oral suspension AMOXICILLIN/POTASSIUM CLAV 03/31/2016 03/31/2016 Active Aspirin Childrens 81 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN 03/31/2016 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Image: Sol Constraint of the Sign	Active	e Kefl	ex 500 mg	g capsule		CEPHALEXIN		07/20/2016	07/20/2016	
Active Aspirin Childrens 8 1 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL 0 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN 03/31/2016 Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN 03/31/2016 Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or Monograph External Patient Education Guantity: 10 Units: Capsule Refills: 0 Prescribed Elsewhere Source: Pre	Active Aspirin Childrens 8 1 mg chewable tablet ASPIRIN 11/30/2015 03/31/2016 Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN 11/30/2015 03/31/2016 Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN 03/31/2016 Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN 03/31/2016 Image: Send Send Send Renew Renew Interactions Stop Dose Range Delete Rx Braibility Keflex 500 mg capsule Image: Send Send Send Send Send Send Send Send	Active	e Tyle	nol 325 m	ng tablet		ACETAMINO	PHEN	06/15/2016	06/15/2016	
Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (6 mL) or Acetam	Active Norco 5 mg-325 mg tablet HYDROCODONE/ACETAMINOPHEN Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Control of the state of the st	Active	e Aug	mentin 25	50 mg-62.5 mg/5 mL o	oral suspension	AMOXICILLIN	V/POTASSIUM CLAV	03/31/2016	03/31/2016	
Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN	Active Fluor-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg) SODIUM FLUORIDE/XYLITOL Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Keflex 500 mg capsule Renew Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Monograph External Patient Education Image: Children's Acetaminophen 160 mg/5 mL (5 mL) or Quantity: 10 Units: Capsule Refills: 0 Prescribed Elsewhere Source: Cecept Cance Stat: 07/20/2016 Stop: 11/01/2016 Duration: Prescribed Elsewhere Source: Provider: Provider: Provider: Prekeason: Provider:	Active	e Asp	irin Childre	ens 81 mg chewable t	tablet	ASPIRIN		11/30/2015	03/31/2016	
Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN III III III Prescribe New Print Send Renew Interactions Stop Resources Dose Range Delete Rx Engibility Keflex 500 mg capsule Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Monograph External Patient Education Clinical Decision Support External Provider Reference Ocept Cancer Stat: 07/20/2016 Stop: 11/01/2016 Duration: Prescribed Elsewhere Source: PRN Reason: PRN Notes to Pharmacy: added using the 'Additional Instructions' segment of the Sig Builder. PRN Reason: Provider: Provider: Havekorst, Walter DDS External Procession Patient Cancer Add	Active Children's Acetaminophen 160 mg/5 mL (5 mL) or ACETAMINOPHEN III III Prescribe New Print Send Renew Interactions Stop Dose Range Delete Rx Engibility Keflex 500 mg capsule Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Monograph External Patient Education Clinical Decision Support External Patient Education Quantity: 10 Units: Capsule Refills: 0 Stat: 07/20/2016 Stop: 11//01/2016 Duration: Prescribed Elsewhere Source: Prescribed Elsewhere Source: Cance NoneStincal Notes to Provider: Havekorst, Walter DDS Location: SVCHC Dental Provider: Havekorst, Walter DDS Provider: Provider:	Active	e Nor	co 5 mg-3	25 mg tablet		HYDROCODO	ONE/ACETAMINOPHEN			
Prescribe New Print Send Renew - PInteractions - Stop Keflex 500 mg capsule Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Quantity: 10 Units: Capsule Refulls: 0 External Provider Reference Vocept Canced Stat: 07/20/2016 Stop: 11/01/2016 - Duration: Non-Clinical This field is for nonclinical comments to the pharmacist. Any additional clinical instructions' segment of the Sig Builder. Provider: Havekorst, Walter DDS	Prescribe New Reflex Soon g capsule Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Quantity: 10 Units: Capsule Refills: 0 Prescribed Elsewhere Source: Non-Clinical Non-Clinical Tris field is for nonclinical comments to the pharmacist. Any additional clinical instructions for this prescription should be pharmacy: added using the 'Additional Instructions' segment of the Sig Builder. Provider: Havekorst, Walter DDS Location: SVCHC Dental	Active	e Fluo	or-a-day (with Xylitol) 0.5 mg flu	uoride (1.1 mg).	SODIUM FLU	ORIDE/XYLITOL			
Prescribe New Print Send Benew - Pinteractions - Stop - Resources - Dose Range Delete Resources - Resources - Dose Range Delete - Resources - Dose Range - R	Prescribe New Print Send Benew - Pinteractions - Stop - Ose Range Delete Refility Keflex 500 mg capsule Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Quantity: 10 Units: Capsule Refills: 0 Start: 07/20/2016 Stop: 11/01/2016 - Duration: Prescribed Elsewhere Source: Prescribed Elsewhere Source: Prescribed Lisewhere Source: Provider: Havekorst, Walter DDS Location: SVCHC Dental	Active	e Chile	dren's Ace	etaminophen 160 mg/	⁵ mL (5 mL) or	ACETAMINO	PHEN		_	
Keflex 500 mg capsule Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Quantity: 10 Units: Capsule Refills: 0 Start: 07/20/2016 Stop: 111/01/2016 • Non-Clinical This field is for nonclinical comments to the pharmacist. Nore-Store Any additional clinical instructions' segment of the Sig Builder. Provider: Havekorst, Walter DDS	Keflex 500 mg capsule Sig: take 1 capsule by oral route every 12 hours Remove Sig Edit Sig Quantity: 10 Units: Capsule Refills: 0 Stat: 07/20/2016 Stop: 11/01/2016 Duration: Prescribed Elsewhere Source: Non-Clinical Any additional clinical instructions for this prescription should be Pharmacy: Added using the 'Additional Instructions' segment of the Sig Builder. Provider: Havekorst, Walter DDS Location: SVCHC Dental	•					_ /				
Non-Clinical Notes to Pharmacy: This field is for nonclinical comments to the pharmacist. Any additional clinical instructions for this prescription should be added using the 'Additional Instructions' segment of the Sig Builder. PRN Reason: Provider: Havekorst, Walter DDS	Non-Clinical Notes to Pharmacy: This field is for nonclinical comments to the pharmacist. Any additional clinical instructions for this prescription should be ended using the 'Additional Instructions' segment of the Sig Builder. PRN Reason: Provider: Havekorst, Walter DDS Location: SVCHC Dental	Sig: take 1	I capsule by oral rou	te every	12 hours Remove Si	g Edit Sig					
Notes to Any additional clinical instructions for this prescription should be Provider: Add Provider: Havekorst, Walter DDS	Notes to Any additional clinical instructions for this prescription should be Provider: added using the 'Additional Instructions' segment of the Sig Builder. Add Add			-				External Provider	Reference	Accept Car	ncel
	Location: SVCHC Dental		07/20/2016	Stop:	11/01/2016 -	Duration:		External Provider Prescribed Elsewhere So	Reference	Accept Car	ncel
Location: SVCHC Dental		Start: Non-Clinical Notes to	07/20/2016 This field is for noi Any additional clin	Stop: nclinical c vical instru	■ 11/01/2016 ▼ omments to the pham ctions for this prescrip	Duration: nacist. tion should be		External Provider Prescribed Elsewhere Sc PRN Re	Reference	Accept	ncel
	Note: taking as directed	Start: Non-Clinical Notes to Pharmacy:	07/20/2016 This field is for noi Any additional clin added using the 2	Stop: nclinical c nical instru Additional	■ 11/01/2016 ▼ omments to the pham ctions for this prescrip	Duration: nacist. tion should be		External Provider Prescribed Elsewhere Sc PRN Re	Reference	ocept Car	ncel
	Note: taking as directed	Start: Non-Clinical Notes to Pharmacy: Provider:	07/20/2016 This field is for noi Any additional clim added using the 2 Havekorst, Walter	Stop: nclinical c nical instru Additional	■ 11/01/2016 ▼ omments to the pham ctions for this prescrip	Duration: nacist. tion should be		External Provider Prescribed Elsewhere Sc PRN Re	Reference	Ccept Car	ncel
Formulary Data		Start: Non-Clinical Notes to Pharmacy: Provider: Location: Not	07/20/2016 This field is for non- Any additional clin added using the ' Havekorst, Walter SVCHC Dental te: taking as direct	Stop: nclinical c iical instru Additional DDS	■ 11/01/2016 ▼ omments to the pham ctions for this prescrip	Duration: nacist. tion should be		External Provider Prescribed Elsewhere Sc PRN Re	Reference	Accept Car	
Formulary Data:	Formulary Data.	Start: Non-Clinical Notes to Pharmacy: Provider: Location: Not	07/20/2016 This field is for non- Any additional clin added using the ' Havekorst, Walter SVCHC Dental te: taking as direct	Stop: nclinical c iical instru Additional DDS	■ 11/01/2016 ▼ omments to the pham ctions for this prescrip	Duration: nacist. tion should be		External Provider Prescribed Elsewhere Sc PRN Re	Reference	ccept Car	

- 4. This will take you to the US National Library of Medicine's Medline Plus Connect and to the information for the selected medication.
 - a. Please note that it may take you to the generic name of the medication and that you may need to click on the hyperlink to get the med info sheet.





- 5. By clicking on the Espaňol hyperlink, this information will translate into Spanish.
- 6. You can print out this information by clicking on the print button.
- 7. Please note the following:
 - a. This information cannot be saved into the patient chart
 - b. This information cannot be printed out by the Front Desk

If you talk to the patient following the information outlined within Medline Plus Connect's health education materials, you will have touched upon most of the expected key points.

Alternately, you can use the monograph which can also be found in the medication module in NextGen, but this document is only available in English.

1. From the medication module and, after you have prescribed the medication, highlight the medication in question.

- 2. Go to Resources
- 3. Select Monograph

Statu	is Me	dication N	ame		Generic Nam	ne	Original Start	Start Date	
- Status: A	ctive (7 items)								
Active	e Kefl	lex 500 mg	j capsule		CEPHALEXIN		07/20/2016	07/20/2016	
Active	e Tyle	enol 325 m	g tablet		ACETAMINO	PHEN	06/15/2016	06/15/2016	
Active	e Aug	mentin 25	0 mg-62.5 mg/5 mL oral susp	ension	AMOXICILLIN	POTASSIUM CLAV	03/31/2016	03/31/2016	
Active	Asp	Aspirin Childrens 81 mg chewable tablet			ASPIRIN		11/30/2015	03/31/2016	
Active	Nor	co 5 mg-3	25 mg tablet		HYDROCODO	ONE/ACETAMINOPHEN			
Active	e Fluo	or-a-day (with Xylitol) 0.5 mg fluoride (1.1 mg)	SODIUM FLU	ORIDE/XYLITOL			
Active	e Chil	dren's Ace	taminophen 160 mg/5 mL (5	mL) or	ACETAMINO	PHEN			
(11						
Jig. Lake I	capsule by oral rou	lte every	12 hours Remove Sig Edit	6ig		External Patient Ec			
-		_		- 11 I		Clinical Decision S	Support	t	
Quantity:	10	Units:	Capsule	Pefills: 0		Clinical Decision S External Provider F	Support Reference	ccept Car	ncel
Quantity:	10 07/20/2016	Units: Stop:	Capsule □ 11/01/2016 ▼ Dur	- 11 I		Clinical Decision S External Provider F Prescribed Elsewhere Son	Support Reference	ccept Car	ncel
Quantity:	10 07/20/2016 This field is for no. Any additional clir	Units: Stop: nclinical c nical instru	Capsule	ration:		Clinical Decision S External Provider F Prescribed Elsewhere Son	Support Reference	ccept Car	ncel
Quantity: Start: Non-Clinical Notes to Pharmacy:	10 07/20/2016 This field is for no. Any additional clir	Units: Stop: nical instru Additional	Capsule 11/01/2016 Uut omments to the pharmacist. ctions for this prescription sho	ration:		Clinical Decision S External Provider f Prescribed Elsewhere Sor PRN Rea	Support Reference	ccept Car	ncel
Quantity: Start: Non-Clinical Notes to Pharmacy: Provider:	10 07/20/2016 This field is for no. Any additional clir added using the	Units: Stop: nical instru Additional	Capsule 11/01/2016 Uut omments to the pharmacist. ctions for this prescription sho	ration:		Clinical Decision S External Provider f Prescribed Elsewhere Sor PRN Rea	Support Reference	ccept Car	ncel
Quantity: Start: Non-Clinical Notes to Pharmacy: Provider: Location:	10 07/20/2016 This field is for no. Any additional clir added using the Havekorst, Walter SVCHC Dental	Units: Stop: nclinical c nical instru Additional	Capsule 11/01/2016 Uut omments to the pharmacist. ctions for this prescription sho	ration:		Clinical Decision S External Provider f Prescribed Elsewhere Sor PRN Rea	Support Reference	ccept Car	ncel
Quantity: Start: Non-Clinical Notes to Pharmacy: Provider: Location:	10 07/20/2016 This field is for no. Any additional clir added using the Havekorst, Walter	Units: Stop: nclinical c nical instru Additional	Capsule 11/01/2016 Uut omments to the pharmacist. ctions for this prescription sho	ration:		Clinical Decision S External Provider f Prescribed Elsewhere Sor PRN Rea	Support Reference	ccept Car	ncel
Quantity: Start: Non-Clinical Notes to Pharmacy: Provider: Location: Note	10 07/20/2016 This field is for no. Any additional clir added using the Havekorst, Walter SVCHC Dental e: taking as direct	Units: Stop: nclinical c nical instru Additional	Capsule 11/01/2016 Uut omments to the pharmacist. ctions for this prescription sho	ration:		Clinical Decision S External Provider f Prescribed Elsewhere Sor PRN Rea	Support Reference	ccept Car	ncel
Quantity: Start: Non-Clinical Notes to Pharmacy: Provider: Location:	10 07/20/2016 This field is for no. Any additional clir added using the Havekorst, Walter SVCHC Dental e: taking as direct	Units: Stop: nclinical c nical instru Additional	Capsule 11/01/2016 Uut omments to the pharmacist. ctions for this prescription sho	ration:		Clinical Decision S External Provider f Prescribed Elsewhere Sor PRN Rea	Support Reference	ccept Car	ncel

4. You can print out this information by clicking on the print button.


- 5. Please note the following:
 - a. This information cannot be saved into the patient chart
 - b. This information cannot be printed out by the Front Desk
 - c. This information cannot be translated into Spanish.

POLICY THIS PROCEDURE SUPPORTS:

1. Clinical Protocols



Document Title: BMI Documentation Requirements Pag					
Document Type: Procedure	Document ID Number:				
Department: Clinic Operations, Medical Department, Behavioral Health Department					
Author: Julie Vlasis, Consultant CQI/Risk Manager	Implementer/Owner: Xavier Perez, MD, CMO				
Approval Date: 04/14/2014	Training Date: 04/14/2014				
Implementation Date: 04/14/2014	ntation Date: 04/14/2014 Revision Date: 10/01/2015				
Effective Date: Next Review Date: 10/01/2017					

STATEMENT OF PURPOSE:

It is the policy of Sonoma Valley Community Health Centers that all patients one time per year have their BMI recorded in their electronic health record. SVCHC required BMI with Dietary and Physical Activity counseling during the Comprehensive Health Assessment for adult patient 18+ years of age and all CHDP visits for children 3-17. BMI Documentation is required for all Chronic Condition Care Guidelines, i.e.: Hypertension, Diabetes, CAD, IVD and Hyperlipidemia.

DEFINITIONS:

NextGen Enterprise Practice Management (EPM): NextGen EPM is the application used primarily for billing and is also used to manage appointments. Other functions of EPM include, but are not limited to, storing patient demographics, posting transactions, and processing charges.

NextGen Electronic Health Records (EHR): NextGen EHR is the application used to store and maintain a patient's electronic chart. Clinical information such as lab results, health history, and diagnosis history are located in EHR.

Provider Approval Queue (PAQ): The PAQ contains all items that need a provider's approval/signature. These items include but are not limited to the following: Lab Orders Scanned images from NextGen ICS: consultation reports, outside provider records, hospital record, diagnostic report, specialty OB lab, other lab results, other specialty lab, Health Risk Assessment, CMR/suspected child abuse report Documents generated within NextGen EHR: Master IM, PHQ9, specialty-specific chart notes (OB Master, BH Master)

Master IM: Patient progress note generated within NextGen EHR which includes information from the selected encounter. The Master IM includes vitals, patient history, physical exam findings, and orders.

EHR Tasks /Tasking: Tasks are a user's to-do items. The EHR Workflow window (also referred to as Inbox) lists tasks assigned to the current user. Tasks can be sent to another user, a group of users, or one's own inbox. Delegates will also have the option to view tasks assigned to the provider they are a delegate for.

NextGen Image Control System (ICS): An application that is used to import, file, and view scanned images into the NextGen system. ICS images can also be opened in NextGen Electronic Health Record (EHR) and NextGen Electronic Practice Management (EPM).

Scanning: Is defined as a process in which a devised is used that optically scans images such as reports, results and other pertinent health documents and converts it to a <u>digital image</u> that is placed into specific categories for identification into the Patient Electronic Health Record in NextGen.

Order Management: Order Management is a template in NextGen EHR that shows all orders that have been placed for the patient. This template is not encounter-based and will show orders from any encounter in the patient's chart.

Provider Test Action: Provider Test Action is a template that is used by providers to document actions that need to be taken outside of face-to-face encounters. Providers may use this template to place orders and also to send tasks to other staff. A Provider Test Action document can also be generated from this template.

i2iT racks: is a population management system that securely integrates clinical data from practice management, systems, electronic health records, labs, pharmacies and other providers, into a single unified view, with reports to identify subpopulations that require follow-up actions. I2iTracks manages the workflow and specific patient follow up actions, to ensure that both staff and patients complete the required tasks.

Electronic Summary-of-Care Record: this consist of the last two patient progress notes, medications list, current problem list, last laboratory results (not more than 3 months old) and Diagnostic testing (not more than 3 months) as appropriate for the Specialty Care provider selected. (See Specialty Care Referral Requirements Grid)

Body Mass Index, BMI: Body mass index (BMI) is an estimate of body fat based on height and weight. It doesn't measure body fat directly, but instead uses an equation to make an approximation. BMI can help determine whether a person is at an unhealthy or healthy weight. A high BMI can be a sign of too much fat on the body, while a low BMI can be a sign of too little fat on the body. The higher a person's BMI, the greater their chances of developing certain serious conditions, such as heart disease, high blood pressure, and diabetes. A very low BMI can also cause health problems, including bone loss, decreased immune function and anemia.

Bureau of Primary Care Uniform Data System, (UDS): Each year, Health Center Program grantees and look-alikes report on their performance using the measures defined in the Uniform Data System (UDS). HRSA offers manuals, webinars, trainings online and at various

state/regional/national meetings, and other technical assistance resources to assist health centers in collecting and submitting their data.

BACKGROUND:

The following are the actual measures that SVCHC is required to report to UDS

Pediatric Measure

Performance Measure: The performance measure is "Percentage of patients aged 3 -17 years of age who had evidence of BMI *percentile* documentation *and* who had documentation of counseling for nutrition *and* who had documentation of counseling for physical activity during the measurement year." This is calculated as follows:

- **Numerator**: Number of patients in the denominator who had their BMI percentile (not just BMI or height and weight) documented during the measurement year **and** who had documentation of counseling for nutrition **and** who had documentation of counseling for physical activity during the measurement year
- **Denominator**: Number of patients who were 3 years of age through adolescents who were aged 17 at some point during the measurement year, who had at least one medical visit during the reporting year, and were seen by the health center for the first time prior to their 18th birthday; for measurement year 2017, this includes patients with a date of birth between January 1, 2000, and December 31, 2014.

Total Number of Patients 3 through 17 Years of Age, Criteria:

- Were born between January 1,2000, and December 31, 2014, and
- Were first seen ever by the health center prior to their 18th birthday, and
- Had at least one medical visit in a clinical setting during 2017.

Exclusions: Pregnant patients

Adult Measure

Performance Measure: The performance measure is "Percentage of patients aged 18 and older (no outer age limit) with a documented BMI during the most recent visit or within the 6 months prior to that visit **and** when the BMI is outside of normal parameters a follow-up plan is documented." This is calculated as follows:

- **Numerator**: Number of patients in the denominator who had their BMI (not just height and weight) documented during their most recent visit **or** within 6 months of the most recent visit **and** if the most recent BMI is outside of normal parameters, a follow-up plan is documented
- **Denominator**: Number of patients who were 18 years of age or older during the measurement year, who had at least one medical visit during the reporting year; for measurement year 2017 this includes patients with a date of birth on or before December 31, 1999.

Total Number of Patients Age 18 and Over, Criteria:

- Were born on or before December 31, 1999 and
- Were last seen by the health center after their 18th birthday, *and*
- Had at least one medical visit in a clinical setting during 2017.

Exclusions:

- Pregnant women
- Terminally ill patients end of life palliative care

BMI Defined by Age

- Were under age 65 and their BMI was greater than or equal to 25, or
- Were age 65 or older *and* their BMI was greater than or equal to 30, *or*
- Were under age 65 and their BMI was under 18.5, or
- Were age 65 or older *and* their BMI was under 23.

ASSUMPTIONS:

Assisting Patients in reaching and maintaining a healthy weight is important for overall health and can help a patient prevent and control many diseases and conditions. If a patient is overweight or obese, they are at higher risk of developing serious health problems, including heart disease, high blood pressure, type 2 diabetes, gallstones, breathing problems, and certain cancers.

Maintaining a healthy weight is so important: It helps the patient lower their risk for developing these problems, helps them feel good about them self, and gives them more energy to enjoy life.

PCMH (Patient Care Medical Home) Related: Yes (X); No () PCMH

NextGen EPM/EHR Procedure is needed for this Procedure: Yes (X): No ()

PROCEDURES:

The BMI Documentation pattern is exactly the same for both Adults and Pediatrics.

The only different is the BMI Code/ BMI Percentages

- ICD-10 code Z68.5- are for recording BMI percentile. Presence is required
- Codes 97802-97804 are for 15 minutes or more of nutritional counseling. Their presence is sufficient but not necessary. (RD Codes)
- ICD-10 code Z71.89 is required for physical activity counseling.

• ICD-10 Code Z71.3 is required for dietary and nutrition counseling.

/ital Signs	; (<u>1</u>) \	/ital Signs (Dutside N	ormal Rang	e 🕕 BMI ()utside I	lormal F	lange			Chronic	Conditions	Diagnosti	cs View A
	- <u> </u>				0				rical inform	mation entere	d this encou	nter 💊 Health	Promotion Pla	-
Time	Ht (in)	Wt (lb)	BMI	BP	Position	Side	Site	Cuff Size	Pulse	Respiration	Temp (F)	Pulse ox nest	FainLevel	Comment
10:13 AM	67.00	195.00	30.54	122/90	sitting	left		adult			98.00			Historical ent
•														
Audiomet	ny ♦ V	'ision 💠	Orthosta	tic 🚸 Neo	:k/Waist/Hip	Circumf	erence	Impo	rt	Refr	resh	Add	Edit	Remove
ledicatio	ns													6
llergies														0
(rders														6
eview of	System	s												0
													_	rate Intake No

Select the Health Promotion Plan. Please note the BMI Plan is no longer available here.

		Health Promotion Plan - SV	снс		
				Panel Control: 🕤 Toggle 🍙 🕈	Cycle 🖌
lealth Promotion	Plan	\frown		2)
atient's age: 41 Yea r	s IMI: 3	0.54 kg/m		٠	Exclusions
Plan: BMI Plan			`		
	Diagnosis:	Code:	_)		
	Body mass index (BMI) 30.0-30.9, adult	Z68.30			
Diet:					
Details:					
	Characters left: 250				
Physical activity: Details:					
	Characters left: 250				
Referrals: Details:				Timeframe:	
	Characters left: 250				
				Add Update Cle	ear
	(Select a row to up	edate or remove)			
Status ∏ Order		Diagnosis	Code	Details	
ordered Refer Rosa testir	rals: Diagnostic Radiology. Location: Santa Imaging. Evaluate and treat. Diagnostic 10	DM neuro manif type II	E11.40	test this order	

Please note that the BMI Code that is connected to the patient's current weight and height is shown.

The Provider will no longer need to add each additional code individually. The provider will add Dietary Counseling and Activity Counseling as required for UDS reporting.

The screen will look as follows:

				Health Pr	omotic	n Plan - SVCHC			
							Panel Control:	Toggle (Cycle
Health Promotion F	lan							Q	۲
Patient's age: 41 Years	E	MI: 3(0.54	kg/m					Exclusions
Plan: BMI Plan									0
D	iagnosis:					Code:			
	Body mass index (BMI) 30.0-30.9, ad	ult			•	Z68.30			
						Nutrition diagnosis description:			ode:
	Dietary management education, gu		and c	ounseling		Dietary counseling and surveillance		Z	71.3
Details	Provided patient with dietary inform	nation							
Ľ	haracters (eff:209								
_						Physical activity diagnosis description:		Co	nde
Physical activity:	Prescribed activity/exercise educatio	n				Other specified counseling		Z	71.89
Details:	patient to start walking 30 minutes	at a slov	w to r	noderate p	ace.				
L.	haracters left: 187								
Referrals:							Timeframe:		
Details:									
L	haracters (eft: 250								

The Provider will select add and the information will fall into the grid below. The Required codes will automatically appear.

Please note that Z71.3 cannot be used without Z71.89 the correct BMI Z68.XX code. These codes as of 2017 ICD-10 Changes must all be used together for both Adults and Pediatrics. The provider will select add.

itatus 👘 🕅	∏ Order	Diagnosis	Code	Details
ompleted	Prescribed activity/exercise education	Body mass index (BMI) 30.0-30.9, adult	Z68.30	patient to start walking 30 minutes at a slow to moderate pace.
ompleted	Dietary management education, guidance, and counseling	Body mass index (BMI) 30.0-30.9, adult	Z68.30	Provided patient with dietary information
	counseiing			

Remember to select **Save & Close**

Status 7	Order	Diagnosis	Code	Details	
completed	Prescribed activity/exercise education	Body mass index (BMI) 30.0-30.9, adult	Z68.30	patient to start walking 30 minutes at a slow to moderate pace.	
completed	Dietary management education, guidance, and counseling	Body mass index (BMI) 30.0-30.9, adult	Z68.30	Provided patient with dietary information	
		Г			•
		L. 1		Deme	
Dain Manage	smant	1		Remo	ve
Pain Manage	ement			Remov	ve
Pain Manage Fall Risk	ement	11			ve
-					ve

Please note that all of the additional information is under the BMI code this is for reporting. When you go to the Patient Assessment all of the Codes will show.

essment/Plan		
Assessments	1. Assess	nent Type 2 diabetes mellitus with diabetic neuropathy, unsp (E11.40).
My Plan A/P Details	Plan O	ders Referrals: Diagnostic Radiology. Location: Santa Rosa Imaging. Evaluate and treat. Diagnostic testing for Echocardiogram.
Referrals	2. Assess	nent Body mass index (BMI) 30.0-30.9, adult (Z68.30).
Office Procedures Review/Cosign Orders	Plan O	
view Immunizations Office Diagnostics	3. Assess	nent Dietary counseling and surveillance (Z71.3).
Health Promotion Plan	4. Assess	nent Other specified counseling (Z71.89).
Health Promotion Plan	4. Assess	nent Other specified counseling (Z71.89).

Patient Education/ Health Wise

Please remember that NextGen has a wide array of health education documents in English and Spanish. These can be saved to the encounter and printed for the patient to take with them. Patient Education Documentation can be found by selecting File.

Save Clear Delete	SVCHC	 Ahern, Carol MD 	Patient History	x PAQ PM DM Close	Medication Medications Orders Equipment
Frank Test (M)	DOB: 09/28/1949 (67 years) Weight: 19	4.00 lb (88.00 Kg)	Allergies 9 Prol	blems (Diagnoses) (Medications)
C	6985 W Spain St Sonoma, CA 95476 (707) 000-0000 (H)	Insurance: Medicare 1 Nickname: Pref. Language: Declined to			PCP: Referring: Rendering: Ahern, Carol MD
Alerts		Patient In	fo 🛛 🔶 Sticky Note 🗍 💠 Referri	ng Provider 🔶 HIPAA 🔶 A	Advance Directives 🛛 🔶 Screening Summan
4 10/24/2016 08:44 P	M : "*Intake" ×				
			HCC	😡 тов	?) HTN ?) DM ?) CAD 😫

-	Edit Default Vew To	oli Admir	Unites	Window Help
	New		1	
de la	Select Patient_	AR + 9	-	
	Blodify Patsent		/28/1949.0	67 years)
	Oose Patient			Insurance
z	Save		76	Nickname
đ	Oose		HE.	Pref. Canguage
	Post			
	Custom Print \ Send			
	Export Patient Documents			
	Gemenate CCD		West 1	Ippe + Office Visit
	Graph		and the second	20.4
	Reports		-	1,00000
	ChartMail		-	(Peda Sumuridatio
	Pamily Unit	,		
	HIE Consent		-	
r.	Parant Partie		1	
1	Patient Education			
Ц	Daturd Course			
	Summary		-	
	Superbill		180	Paulton 5d
	System \ Practice Template		1	(Passing) join
2	Work Flow	A8.+ F3		
	User Workgroups	AE + P5	-	
ş	Provider Approval Queue	15	Orthomas	c Neck/Wwist/
	Change Enterprise Practice.	0 3	Connection	- MOUNTED
2	Logout	AR - 1		
1000	Exit	Alt • X		
	Orders			
	Review of Systems			

Select Patient Education from the drop down. This will take you to the Health Wise Information.



Use the **Search Criteria Box** to search for the information that you want to provide the patient. For this measure you can use Diet, Exercise, BMI or if they have a Chronic Condition that condition to search for the appropriate materials. Items are based on Age and Sex.

Patient Education Browser						_ 0	×
Search Criteria Diet		🔹 🔎 Search 🤌	🗞 English Ter	m Age: [65 - 79 Ye	ears] Male 👻		
Search Results - Found 50 Documents			_				
Title V	Categories			Document Type	Source	Cpt Codes	
High-Calorie and High-Protein Diet: After Your Visit	Nutrition and Exercise			AfterVisit	Healthwise		
Diet for Fecal Incontinence: After Your Visit	Gastrointestinal, Nutrition and Exer	rcise		AfterVisit	Healthwise		
High-Fiber Diet: After Your Visit	Gastrointestinal, Nutrition and Exer	rcise		AfterVisit	Healthwise		
Soft-Textured, Bland Diet: After Your Visit	Gastrointestinal, Nutrition and Exer	rcise		AfterVisit	Healthwise		
Liver Disease Diet: After Your Visit	Gastrointestinal			AfterVisit	Healthwise		
<pre>4</pre>				• * • • •		Þ	È

Patient Education Browser				
Search Criteria Exercise	🔻 🔎 Search 🦓 English	Ferm Age: [65 - 79 \	/ears] Male 👻	
Search Results - Found 111 Documents				
Title	V Categories	Document Type	Source	Cpt Codes
Finger Fracture: Exercises	Nutrition and Exercise, Orthopedics and Rheumatology, Trauma and .	AfterVisit	Healthwise	97110
Asthma Action Plan: After Your Visit	Pulmonology, Emergency and Urgent Care	AfterVisit	Healthwise	1039F
Carpal Tunnel Syndrome: Exercises	Nutrition and Exercise, Orthopedics and Rheumatology	AfterVisit	Healthwise	97110
Biceps Tendinitis: Exercises	Nutrition and Exercise, Orthopedics and Rheumatology	AfterVisit	Healthwise	97110
Low Back Arthritis: Exercises	Nutrition and Exercise, Orthopedics and Rheumatology	AfterVisit	Healthwise	97110
<pre></pre>	······ ·· ··· · ··· ··			Þ

Patient Education Browser					
Search Criteria BMI		·	🔹 🔎 Search 🆓 En	iglish Term Age: [6	5 - 79 Years] Male 👻
Search Results - Found 1 Document					
Title	∇ Categories	Document Type	Source	Cpt Codes	ICD9 Codes
Body Mass Index: After Your Visit	Nutrition and Exercise	AfterVisit	Healthwise		V85, V85-V85.99, 278.00, 278.01, 278.02 /
•					Þ

When you find the document that you want Highlight it and use the **Select** button and the document will fall in the view box for you to review with the patient.

Genetics Hematology	Return to English Index Spanish English	
Infectious Disease Labs Mental Health and Psychology Mental Health and Psychology Mental Health and Psychology	Body Mass Index: After Your Visit	
IGProd (NGSQL2.NGProd)	Select Send to Patient Portal Save to Encounter	Cancel

itle	Categories	Document Type	Source	Cpt Codes	ICD9 Codes	Age			Gender	
dy Mass Index: After Your Visit	Nutrition and Exercise	AfterVisit	Healthwise		V85, V85-V85.99, 278.00, 2	78.01, 278.02 Adolescent (13 to	18 years), Early adult (19 t) 24 years), Adult (19 to 44 ye	ar Male, Fema	ile
Hage Ernaish	Body Mass Index After Your	Visit								
Allergy and Immunology										
Cardiovascular										
Dental and Oral Health Dermatology		ser.c	SONOMA-VALLEY							
Diabetes and Endocrinology		~	COMMUNIT HEALTH CENTE							
Ear		1.44								
Emergency and Urgent Care Forms and Consents										
Gastrointestinal										
Genetics		Return to Englis	sh Index							Span Englis
Hematology Infectious Disease										Engin
Labs										
Mental Health and Psychology										
Nephrology Neurology		Body	Mass In	dex: Af	ter Your Vis	It				
Nose and Throat Nutrition and Exercise		Your Ca	are Instru	uctions						
OB/Gyn Oncology Ophthalmology Othopedics and Rheumatology		much you weigh	with how tall you a		18.5 and 24.9 is considered hea	blems. It uses a formula to compa thy. A BMI between 25 and 29.9 i	6'4" 6'2"			
Pain Management Pediatrics Pre- and Postnatal Care		overw eight or ob		y be at increased ri		health problems. If your BMI is in t lems, such as high blood pressur				
Pre- and Post-Op Pulmonology Senior Health and Geriatrics					health problems. You may be at h alcohol or use tobacco products	nigher risk for health problems if y	5'4"			
Tests and X-Rays Toxicology					d safety. Be sure to make and g your test results and keep a list of	o to all appointments, and call you f the medicines you take.	5'0"			
Trauma and Injuries Urology		How ca	n you ca	re for yo	urself at home	?	4'10" L	Weight (
					plenty of fruits, vegetables, who			Healthy weight Over	weight	Obese

Remember to **Save to Encounter** so that it can be printed at checkout for the patient.

Patient Education Browser						
Search Criteria BMI		-	🔎 Search 🆓 B	English Term Age:	[65 - 79 Years] Male 🔻	
Search Results - Found 1 Document						
Title	∇ Categories	Document Type	Source	Cpt Codes	ICD9 Codes	
Body Mass Index: After Your Visit	Nutrition and Exercise	AfterVisit	Healthwise		V85, V85-V85.99, 278.00, 3	278.01, 278.02 A
<						
						•
Language English	Body Mass Index: After Your	' Visit			8	
Allergy and Immunology Cardiovascular Dental and Oral Health Dernatal and Oral Health Dernatology Diabetes and Endocrinology Ear Emergency and Urgent Care Forms and Consents Gastrointestinal Genetics Hematology Infectious Disease Labs Mental Health and Psychology Nephrology		English Index	NITY NTER	After Yo	<u>Spanish</u> English	
NGProd (NGSQL2.NGProd)		Sele	ect Seno	to Patient Portal	🛃 Save to Encounter	Cancel

📄 🗁 🧰 10/24/2016 08:44 PM Carol Ahern MD
*Intake
📥 🚔 Body Mass Index: After Your Visit

Once the information is saved to the encounter it is a permanent part of the patient electronic health record.

This Procedure support the following Policy:

SVCHC Evidence-based Guideline Development